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PREFACE 
This dissertation summarizes the work I have done during the past five 
years in Dr. Kovari’s lab. I am currently working on two independent projects. 
The first project addresses structure and function studies of multi-drug 
resistant HIV-1 protease. Protein crystallography, enzymatic assays, in silico 
modeling, and medicinal chemistry are the major tools employed to reveal the 
mechanism of HIV-1 protease drug resistance, to design, synthesize, and test 
the new drug candidates. 
The second project focuses on structural studies of the extracellular 
domain of human myelin protein zero, which is responsible for 
Charcot-Marie-Tooth disease type 1B. 
More Introductory information concerning the two projects, experimental 
procedures, results, and discussion are included in this dissertation. I hope 
that reading my dissertation is a pleasant scientific experience for the readers. 
 
Thanks, 
Zhigang Liu
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CHAPTER 1: INTRODUCTION 
1.1 Retroviruses 
1.1.1 Characteristics of retroviruses 
Retroviruses are a large family of enveloped RNA viruses that share some 
common taxonomic components such as structure, composition, and 
replicative properties(1). The diameter of these virions ranges from 80 to 100 
nm with the viral glycoproteins embedded in the lipid envelope. The average 
size of the viron RNA is about 7–12 kb. The viral RNA is positive, linear, 
single-stranded, nonsegmented. 
The hallmarks of retrovirus include the following key points. First, 
retroviruses replicate in the host through the enzyme reverse transcriptase 
which converts its RNA genome to linear double-stranded DNA. Second, the 
enzyme integrase incorporates the DNA into the host genome. Third, the viral 
genome then replicates itself as part of the host genome. The integrated viral 
DNA in the host genome is refered to as a provirus. 
Based on the genome organization, the retroviruses comprise two 
categories: simple and complex retrovirus. Three major coding domains are 
essential for all retroviruses: gag, which encodes viral structural proteins 
including the matrix, the capsid, and the nucleoprotein protein; pol, which 
encodes viral enzyme consisting of the reverse transcriptase and integrase; 
and env, which encodes the surface and transmembrane segments of the 
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envelope protein. Besides these essential major coding domains, the 
replication of retroviruses entails another smaller coding domain called pro, 
which encodes the enzyme protease. Retroviruses contain only these 
essential elements are referred to as simple retroviruses and complex 
retroviruses carry other regulatory nonvirion proteins arising from multiply 
spliced messages. Figure 1.1 
1.1.2 Classification of Retroviruseses 
Based on the relationship in evolution, retroviruses are classified into 
seven groups as shown in Table 1.1. Except for lentiviruses and the 
spumaviruses, retroviruses have oncogenic potential. As shown in Table 1.1, 
the human T-cell leukemia virus–bovine leukemia virus (HTLV-BLV) and the 
lentiviruses and spumaviruses are complex retroviruses and all other members 
are simple retroviruses. 
1.2 Lentiviruses 
1.2.1 Characteristics of lentiviruses 
Lentivirus is a genus in retrovirus family and consists of several groups 
animal viruses. All these groups have some characteristics in common (2-3). 
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Figure 1.1 Genome of retrovirus (A) A simple retroviral genome. The 
genetic map of an ALV contains four major coding regions, gag, pro, pol, and env. 
Different reading frames are indicated by vertical displacement of the coding region. 
The pro gene is encoded in the gag reading frame. The terminal noncoding 
sequences include two direct repeats (R), a U5 (5′unique), and a U3 (3′unique) 
sequence. (B) A complex retroviral genome. The genetic map of HTLV contains, 
besides the major coding domains, information for two regulatory proteins, Tax and 
Rex, encoded in regions (boxes) joined by RNA splicing. In this case, gag, pro, and 
pol are all in different reading frames. 
Source: Retroviruses 1997. John M. Coffin, Stephen H. Hugues and Harold E. 
Varmus. Cold Spring Harbor Laboratory Press. 
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Table 1.1 Classification of Retroviruses 
Genus Example Virion morphologya Genome 
Avian sarcoma and 
leukosis viral groupb 
Rous sarcoma 
virus 
central, spherical core “C 
particles” 
simple 
Mammalian B-type viral 
group 
mouse mammary 
tumor virus 
eccentric, spherical core 
“B particles” 
simple 
Murine leukemia-related 
viral group 
Moloney murine 
leukemia virus 
central, spherical core “C 
particles” 
simple 
Human T-cell leukemia 
bovine leukemia viral 
human T-cell 
leukemia virus 
central, spherical core complex 
D-type viral group Mason-Pfizer 
monkey virus 
cylindrical 
core  
“D 
particles” 
simple 
Lentiviruses HIV cone-shaped core complex 
Spumaviruses human foamy 
virus 
central, spherical core complex 
 
a
 Distinctive features seen in transmission electron micrographs. 
Source: Retroviruses 1997. John M. Coffin, Stephen H. Hugues and Harold E. 
Varmus. Cold Spring Harbor Laboratory Press. 
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Clinically, lentiviruses are associated with a disease with a long incubation 
period, immune deficiency, arthritis and autoimmunity. In addition, they are 
involved in diseases affecting the hematopoietic system and central nervous 
system. 
Biologically, they are host species specific, exogenous and nononcogenic. 
The virus particles show a cone-shaped nucleoid under the electron 
microscope. The unintegrated circular and linear viral cDNA accumulates in 
the infected cell. In addition, the infection of the cells could be latent and 
persistent. 
Molecularly, the genome is relatively large, more than 9kb long. The gag 
gene is truncated. The envelope gene is highly glycosylated and highly 
polymorphic. In addition, there is a novel central open reading frame in the viral 
genome that separates the pol and env regions.  
1.2.2 Classification of lentiviruses 
The classification of lentiviruses is shown in Table 1.2; the classification is 
based on the different hosts that are infected by the viruses.  
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Table 1.2 Lentiviruses 
Virus Host Primary cell Clinical disorder 
EIA virusa Horse Macrophages Autoimmune hemolytic anemia, 
Encephalopathy 
Visna/maedi 
virus 
Sheep Macrophages Encephalopathy/pneumonitis 
CAE virusb Goat Macrophages Arthritis, encephalopathy 
BIVc Cow Macrophages Lymphocytosis, CNS disease 
FIVd Cat T cell Immune deficiency, encephalopathy 
SIVe Primate T cell Immune deficiency, encephalopathy 
HIVf Human T cell Immune deficiency, encephalopathy and 
enteropathy 
aEquine infectious anemia virus, bCaprine arthritis-encephalitis virus, cBovine immune 
deficiency virus ,dFeline immune deficiency virus, eSimian immune deficiency virus, 
fHuman immune deficiency virus 
Source: Levy, J. A. HIV and pathogenesis of AIDS -3rd Edition 2008. ASM press, 
American Society for Microbiology (Editors) & HIV Sequence Compendium 2008 
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1.3 HIV 
1.3.1 HIV epidemiology 
HIV was discovered in 1981 (4), and its classification as a member of 
lentivirus was proposed one year later (5-8). Investigators first attributed AIDS 
to some known pathogens such at Epstein-Barr virus, cytomegalovirus and 
human T-cell leukemia virus (9-10). Later Montagnier and coworkers proved 
that a new human retrovirus, similar to human T-cell leukemia virus, which 
they called lymphadenopathy-associated virus (LAD), was associated with 
AIDS by destruction of CD4+ cells(11). In 1984, HTLV-III was identified by 
Gallo et al to be the pathogen of AIDS (12-15). In addition, Levy and his 
colleagues reported that they had identified a retrovirus called 
AIDS-associated retrovirus (ARV) that caused AIDS(16). It was proven later 
that LAD and HTLV-III were the same virus. In 1986, a new name, HIV, was 
given to these viruses by the International Committee on Taxonomy of 
Viruses(17). 
Another strain called HIV-2 was discovered in West Africa shortly after the 
discovery of HIV-1 (18). Both HIV-1 and HIV-2 lead to AIDS despite the more 
than 55% difference at the level of RNA sequence.  The rest of this thesis will 
discuss HIV-1 only. 
According to the AIDS epidemic update December 2009 by the Joint 
United Nations Programm on HIV/AIDS (UNAIDS) and the World Health 
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Organization (WHO), 33.3 million people were living with HIV, 2.6 million were 
newly infected and 1.8 million died of HIV in 2009. The global distribution of 
HIV infection is summarized in Figure 1.2 (19). 
1.3.2 HIV pathogenesis 
In the initial stage of an acute HIV infection, HIV most likely attaches to 
host cells at the site of viral entry, such as activated lymphocytes, dendritic 
cells, or macrophages in the mucosae or the lymphoid tissues (20-21). The 
infection is established by the translocation of the HIV from the entry site to 
local lymph nodes (21-22). Within five to seven days of infection, as many 
as >107 viral RNA molecules per ml of plasma may be detected. After 10 to 14 
days, up to 200 billion CD4+ cell can be infected and destroyed (23). During 
acute infection, CD8+ cell count increases. In addition, some innate antiviral 
cytokines are also produced. However, the cytokines are too late to prevent 
the establishment of infection (24-25), although they in turn cause acute 
retroviral syndrome. Due to the host immune response against HIV as well as 
the loss of target cells (26), the viremia is reduced dramatically within weeks in 
acute infection.  
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Figure 1.2 Global estimates for HIV infection as of December 2009 
 
The CD4+ count usually returns to values close to normal after three to six 
month of infection, and then it decreases steadily at a rate of 25 to 60 cells/µl 
per year due to unknown reasons (27). This asymptomatic period, when the 
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HIV continues to replicate at a low rate, is called the persistent period and it 
leads to the heterogeneity of the HIV population under the selection pressure 
of the immune system (28).The anti-HIV activity of the immune system is 
thought to be meditated by CD8+  cells (29-30). 
The symptomatic period develops in many HIV infection patients within ten 
years when the CD4+ cell count drops below 350 cell/µl; the viral load 
increases significantly, and the antiviral CD8+ immune response decreases 
(31-33). In parallel there is a destruction of lymphoid tissue (34-35). In the end 
stage of AIDS, CD4+ cells are still the major source of virus except in the GI 
tract (36). The overall progression of HIV infection is summarized in Figure 1.3 
(37). 
 
Figure 1.3 progression of HIV infection (37). 
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1.3.3 HIV structure 
Figure 1.4 shows that the HIV viral p24 Gag capsid protein forms a 
cone-shaped core, which is characteristic of lentiviruses.  The viron is about 
100 to 120 nm in diameter (38). 
The HIV viron is a lipid bilayer enveloped virus, which is derived from the 
host cell membrane. Two proteins are present on the viral memberane, the 
external surface envelope protein gp160 and the transmembrane protein gp41, 
derived from a 160kDa precursor glycoprotein, gp160. They form spike-like 
structures and later are arranged as tripod-like structure on the viral membrane 
(39). Underneath the envelope is an inner shell composed of matrix protein 
(MA, p17), which is required for incorporation of the Env protein in the mature 
virions (40). Inside the inner shell is a conical core made of capsid protein (CA, 
p24), within which resides the viral genomic RNA and the viral structural 
protein nucleocapsid (NC. P7) interacting with viral RNA (41). Inside the capid 
core, there are three essential viral enzymes, the viral RNA-dependent DNA 
polymerase (also called reverse transcriptase, RT, p66, p51) (Figure 1.5). In 
addition, Vif and Nef proteins are closely associated with the core (42-44). Vpr 
protein is also found within the virion and most likely outside of the core 
(45-46). Finally, some cytoskeletal proteins are found within the virions (47) 
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Figure1.4 Morphology of HIV. (A) Scanning electron micrograph of budding 
particles. (B) Transmission electron micrograph of HIV replication in a T cell.  
Source: Levy, J. A. HIV and pathogenesis of AIDS -3rd Edition 2008. ASM press, 
American Society for Microbiology (Editors) & HIV Sequence Compendium 2008 
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Figure 1.5 an HIV virion with the structural and other virion proteins 
identified 
Source: Levy, J. A. HIV and pathogenesis of AIDS -3rd Edition 2008. ASM press, 
American Society for Microbiology (Editors) & HIV Sequence Compendium 2008 
1.3.4 HIV genome 
The HIV genome is about 10 kb long consisting of 46 open reading frames 
and two long terminal repeats as shown in Figure 1.6. 16 viral proteins are 
translated based on the open reading frames. The viral mRNA can be 
unspliced, singly spliced or multiply spliced. The key entity regulating the 
splicing is the rev gene, which is also the product of a multiply spliced mRNA 
(48). 
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A full length viral mRNA, translated to Gag and Gag-Pol polyprotein later, 
is the primary transcription product of HIV. The ratio of Gag and Gag-Pol 
polyprotein is about 20:1 (49). The Gag-Pol polyprotein is 160kDa and 
processed by HIV protease into seven individual proteins: matrix protein (p17), 
capsid protein (p24), late domain (p7), nucleocapsid protein (p9), protease 
(p10), reverse transcriptase/RNase (p66/p51), and integrase (p32). The first 
four proteins are Gag protein and the last three are Pol protein. 
Similarly, Env precursor (gp160), a translation product of a singly spliced 
message from the full-length viral mRNA, is proteolytically cleaved by the host 
endoprotease, furin, into the surface glycoprotein (gp120) and the 
transmembrane glycoprotein (gp41) (50). 
A variety of viral regulatory and accessory proteins affecting the replication 
are products of the spliced mRNA, including Tat (p14), Tev (p20), Rev (p19), 
Nef (p27), Vif (p23), Vpr (p15), and Vpu (p16). Tat is a transactivating protein 
up-regulating HIV replication (51). Rev transports the full-length unspliced 
mRNA from the nucleus to cytoplasm (48,52). The Nef protein functions in 
signal transduction and cell activation (53-54). Vif, Vpr, and Vpu/Vpx proteins 
are important in virion assembly, cell cycling, budding, and infectivity (51,54).   
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Figure 1.6  The HIV genome and the processing of viral proteins. 
1.3.5 HIV replication 
The overall replication of HIV is summarized in Figure 1.7 
The HIV replication cycle starts with the binding of the HIV envelope 
protein gp120 to the CD4 molecule on the host T cells (55-57). Further studies 
revealed that the D1 region of the CD4 molecule participates in the virus 
binding directly (58-60). After the primary binding event, gp120 is displaced, to 
make gp41, which is necessary for virus and cell fusion, accessible to the host 
cell. The displacement of gp120 may be due to the dissociation of gp120 and 
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gp41, or cleavage of gp120 (61-63). The HIV virion then enters the host cell as 
a ribonucleocapsid after the virus fuses with the host cell membrane. 
In the presence of viral capsid protein and the host cyclophilin A, which is a 
peptidylprolyl isomerase binding to capsid protein, the HIV RNA exits from the 
viral capsid (64-66). 
Reverse transcription of the viral RNA to double-strained cDNA is then 
carried out by the enzyme’s RNA and DNA dependent DNA polymerase, and 
RNase H, with assistance from matrix protein and the nucleocapsid protein as 
a chaperon protein (67-68).  
The viral cDNA, together with viral matrix protein, Vpr protein, and 
integrase as a preintegration complex, is transported to the nucleus as a 
nuclear pore complex due to a short nuclear localization signal sequence in 
integrase (69-71). Matrix protein and Vpr are not essential for the 
preintegration complex (72-73), although the latter may help nuclear 
importation (71,73).  
Inside the nucleaus, linear viral cDNA is integrated into the host cell 
genome via the catalytic function of integrase and other host cell factors 
(65,74). The transcriptionally active regions of the genome are the regions 
where the integration primarily takes please (75-76). Among the host cell 
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factors, emerin, an integral inner nuclear envelope protein, is necessary for the 
HIV cDNA integration (77).  
The viral mRNA transcription is initiated with some doubly spliced 
transcripts of the major regulatory genes, such as tat, rev, and nef (51). 
Viral assembly takes place in the host cell membrane. The viral RNA is 
incorporated into the capsid core. The capsid core, in turn, buds from the host 
cell membrane, where it obtains the lipid bilayer membrane. The gp120 and 
gp41 are incorporated on the viral membrane via the interaction between the 
cytoplasmic tail of gp41 and the Gag protein (78-79). 
Two major models are proposed for the budding process(41). The lipid raft 
model, states that Gag and Gag-Pol precursors localize to the lipid rafts on the 
plasma membrane where sphingolipids and cholesterol are enriched (80-82). 
The second model, the Trojan exosome hypothesis, states that the assembly 
of HIV virions happens in multivesicular bodies which later fuse with the 
plasma membrane and releases the virus as an exosome (83).  
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Figure 1.7 HIV replication cycle Adapted from http://aidsinfo.nih.gov/ 
1.Binding and fusion 2. Reverse transcription 3. Integration  
4. Transcription 5. Assembly 6. Budding 
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1.4  Antiretroviral therapy 
1.4.1 Principles of antiretroviral therapy 
Treatments for HIV infection have evolved at an extraordinary high rate 
compared to other infectious diseases. More than 20 different drugs belonging 
to several categories have been discovered and developed during the past 30 
years as shown in Table 1.3. These drugs inhibit essential steps in HIV viral 
replication, such as virus cell entry (84-85), reverse transcription (86), viral 
cDNA intergration (87), viral polyprotein cleavage (88-89), and viral maturation 
(90-93). However, the emerging drug resistance, due to the lack of 
proofreading ability of the HIV-1 reverse transcriptase (94-96), requires the 
development of new and potent drugs to overcome the resistance problem 
(97-101). 
Although these drug cannot eradicate HIV completely(102), careful use of 
of them can reach the following goals: reducing the HIV related morbidity, 
prolonging survival, improving the quality of life, restoring and preserving 
immunologic function, and preventing HIV transmission (103). However, a 
single drug is not potent enough to achieve all these goals due to the rapidly 
emerging drug resistance under the drug selection pressure (18,99-101).  
As a result, a combined antiretroviral therapy, highly actively antiretroviral 
therapy (HAART) (104-107), is currently the mainstream treatment of HIV 
infection, which combines at least three drugs. The underlying rationale is: first, 
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it is unlikely for the HIV virus to be resistant to three drugs in treatment naïve 
patients; second, the mutation rate, including the drug resistant mutations, is 
highly dependent on the viral replication rate (108). HAART, with at least three 
drugs, can suppress the viral RNA below 50 copies/ml for several years (109) 
and thus reduce the transmission rate (110). 
However, if viral replication is not suppressed fully by the initial HAART, 
the drug combination must be changed to achieve maximal suppression of 
replication. However, if the full suppression of viral replication is not feasible, 
even after trials of all the different drug combinations, it is acceptable to have 
intervals of persisting viremia (111). 
Table 1.3 Antiretroviral drugs used in the treatment of HIV infection   
Adapted from FDA website. 
Brand 
Name 
Generic Name Manufacturer Name Approval 
Date 
Time to 
Approval 
Atripla efavirenz, 
emtricitabine and 
tenofovir disoproxil 
fumarate 
Bristol-Myers Squibb 
and Gilead Sciences 
12-July-06 2.5 months 
Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 
Brand 
Name 
Generic Name Manufacturer Name Approval 
Date 
Time to 
Approval 
Combivir lamivudine and 
zidovudine 
GlaxoSmithKline 27-Sep-97 3.9 months 
Emtriva emtricitabine, FTC Gilead Sciences 02-Jul-03 10 months 
Epivir lamivudine, 3TC GlaxoSmithKline 17-Nov-95 4.4 months 
Epzicom abacavir and 
lamivudine 
GlaxoSmithKline 02-Aug-04 10 months 
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Hivid zalcitabine, 
dideoxycytidine, 
ddC (no longer 
marketed) 
Hoffmann-La Roche 19-Jun-92 7.6 months 
Retrovir zidovudine, 
azidothymidine, 
AZT, ZDV 
GlaxoSmithKline 19-Mar-87 3.5 months 
Trizivir abacavir, 
zidovudine, and 
lamivudine 
GlaxoSmithKline 14-Nov-00 10.9 
months 
Truvada tenofovir disoproxil 
fumarate and 
emtricitabine 
Gilead Sciences, Inc. 02-Aug-04 5 months 
Videx EC enteric coated 
didanosine, ddI EC 
Bristol Myers-Squibb 31-Oct-00 9 months 
Videx didanosine, 
dideoxyinosine, ddI 
Bristol Myers-Squibb 9-Oct-91 6 months 
Viread tenofovir disoproxil 
fumarate, TDF 
Gilead 26-Oct-01 5.9 months 
Zerit stavudine, d4T Bristol Myers-Squibb 24-Jun-94 5.9 months 
Ziagen abacavir sulfate, 
ABC 
GlaxoSmithKline 17-Dec-98 5.8 months 
Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
Brand 
Name 
Generic Name Manufacturer Name Approval 
Date 
Time to 
Approval 
Intelence etravirine Tibotec Therapeutics 18-Jan-08 6 months 
Rescriptor delavirdine, DLV Pfizer 4-Apr-97 8.7 months 
Sustiva efavirenz, EFV Bristol Myers-Squibb 17-Sep-98 3.2 months 
Viramune nevirapine, NVP Boehringer Ingelheim 21-Jun-96 3.9 months 
Protease Inhibitors (PIs) 
Brand 
Name 
Generic Name Manufacturer Name Approval 
Date 
Time to 
Approval 
Agenerase amprenavir, APV GlaxoSmithKline 15-Apr-99 6 months 
Aptivus tipranavir, TPV Boehringer Ingelheim 22-Jun-05 6 months 
Crixivan indinavir, IDV, Merck 13-Mar-96 1.4 months 
Fortovase saquinavir (no 
longer marketed) 
Hoffmann-La Roche 7-Nov-97 5.9 months 
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Invirase saquinavir 
mesylate, SQV 
Hoffmann-La Roche 6-Dec-95 3.2 months 
Kaletra lopinavir and 
ritonavir, LPV/RTV 
Abbott Laboratories 15-Sep-00 3.5 months 
Lexiva Fosamprenavir 
Calcium, FOS-APV 
GlaxoSmithKline 20-Oct-03 10 months 
Norvir ritonavir, RTV Abbott Laboratories 1-Mar-96 2.3 months 
Prezista darunavir Tibotec, Inc. 23-Jun-06 6 months 
Reyataz atazanavir sulfate, 
ATV Bristol-Myers Squibb 
20-Jun-03 6 months 
Viracept nelfinavir mesylate, 
NFV 
Agouron 
Pharmaceuticals 
14-Mar-97 2.6 months 
Fusion Inhibitors 
Brand 
Name 
Generic Name Manufacturer Name Approval 
Date 
Time to 
Approval 
Fuzeon enfuvirtide, T-20 Hoffmann-La Roche & 
Trimeris 
13-Mar-03 6 months 
Entry Inhibitors - CCR5 co-receptor antagonist 
Brand 
Name 
Generic Name Manufacturer Name Approval 
Date 
Time to 
Approval 
Selzentry maraviroc Pfizer 06-August-07 8 months 
HIV integrase strand transfer inhibitors 
Brand 
Name 
Generic Name Manufacturer Name Approval 
Date 
Time to 
Approval 
Isentress raltegravir Merck & Co., Inc. 12--Oct-07 6 months 
1.4.2 Mechanisms of action of antiretroviral drugs 
Reverse transcriptase inhibitors: Nucleoside and nucleotide reverse 
transcriptase inhibitors (NRTIs) were the first drugs developed to inhibit HIV 
replication through the termination of viral DNA production and competition of 
nucleosides used by the viral polymerase. Among these, 
3’-azido-3’-deoxythymidine (AZT) was the first drug in this category and 
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reported to be effective in preventing the onset of HIV infection symptoms 
(112). It was initially synthesized as a potential drug against cancer (113). 
Subsequently, seven other nucleoside reverse transcriptase inhibitors have 
been used in various combinations. Nucleoside inhibitors must be 
phosphorylated in vivo to be active, Consequently, several nucleotide 
inhibitors of reverse transcriptase have also been developed because they are 
less dependent on cellular kinase activity for activation.  
Four nonnucleoside reverse transcriptase inhibitors (NNRTIs) are on the 
market: etravirine, delavirdine, efavirenz, and nevirapine. They function by 
blocking the hydrophobic pocket within the polymerase domain of the p66 
reverse transcriptase subunit. Combined with NRTIs, these NNRTIs are potent 
inhibitors of HIV replication (114). 
Protease inhibitors: The FDA has approved nine HIV protease 
inhibitors (PIs). HIV protease is an aspartic protease that cleaves newly 
synthesized HIV-1 polyproteins at nine major cleavage sites to generate the 
mature protein components of an infectious HIV-1 virion. The HIV-1 gag gene 
codes for three structural proteins: matrix protein (MA), capsid protein (CA), 
and nucleocapsid protein (NC), while the gag-pol gene encodes both the 
structural proteins (MA, CA, and NC) and three enzymes: protease (PR), 
reverse transcriptase (RT), and integrase (IN). Without effective HIV-1 PR, 
HIV-1 virions remain uninfectious, hence making HIV-1 protease inhibitors the 
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most potent anti-AIDS drugs and essential therapeutic components of HAART 
(100,105). PIs are the most potent drugs currently against HIV replication and 
are used as one component of HAART. However, the bioavailability of certain 
PIs and the solubility are major concerns. For example, none of the PIs 
achieve a high concentration in the cerebrospinal fluid.  
Integrase inhibitors: Raltegravir is an integrase inhibitor that disrupts 
the incorporation of viral cDNA into the host genome. It is proposed that 
raltegravir interacts with magnesium, a critical metal cofactor of integrase, in 
the integrase active site to block the catalytic function of integrase (115-117). 
HIV integrase is a 32 kDa protein of 288 amino acid residues. There are three 
functional domains: the N-terminal domain, the catalytic core domain and the 
C-terminal domain (118). 
Fusion inhibitors: Enfuvirtide, which was approved by FDA in 2003, is 
a linear, 36 amino acid synthetic peptide with a sequence identical to part of 
the HR2 region of gp41 that competes for binding to HR1(119-120). The 
antiviral activity has been demonstrated in clinical trials, despite its variability in 
sensitivity against different viral strains (121-125).  Enfuvirtide blocks the 
gp41-mediated membrane fusion of the virus to the host cell. In addition, there 
are other drug candidates that block the gp120-CD interaction and 
gp120-coreceptor interactions (126). 
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1.5 Charcot-Marie-Tooth disease 
This section is an introduction to the second project of my thesis, 
Charcot-Marie-Tooth disease. 
Charcot-Marie-Tooth disease (CMT), a hereditary motor and sensory 
neuropathy (HMSN), is the most common genetic neuropathy with an incidence 
of 1 in 2500 (127). The disease is named for the three physicians who first 
identified it in 1886 - Jean-Martin Charcot and Pierre Marie in Paris, France, 
and Howard Henry Tooth in Cambridge, England. CMT is a heterogeneous 
group of disorders that affect peripheral nerves. The nervous system has two 
parts: the central nervous system (CNS) including the brain and the spinal cord; 
and the peripheral nervous system (PNS), which innervates the muscles and 
sensory organs. Disorders that affect the peripheral nerves are called 
peripheral neuropathies. Both motor and sensory functions are compromised 
in CMT.  Atrophy of the foot and lower leg muscles results in foot drop and a 
high-stepped gait with frequent tripping or falls. Foot deformities are also 
commonly seen clinically due to weakness of the small muscles in the feet. In 
the advanced stage of CMT, muscles in the patient’s hands also atrophy. 
Although the onset of symptoms is often in adolescence or early adulthood, 
the delayed mid-adulthood onset is not rare. Pain may occur, ranging from 
mild to severe. The mobility of the patients may be also limited due to the 
muscle atrophy and weakness. Usually CMT does not affect the life 
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expectancy and thus is a non-fatal disease, although respiration failure may 
happen rarely if the respiratory muscles are severely affected. 
The PNS contains two essential components: neurons and Schwann cells. 
These two components form extensive cell-cell interactions, which are 
necessary for the proper functioning of the PNS. Neuronal cells dominate the 
cell-cell interactions by regulating the survival, proliferation and differentiation 
of Schwann cells, which are important for the process of myelination (128-129). 
In turn, Schwann cells function structurally to determine the distribution of ion 
channels, the maintenance of axons, and neuron development and 
regeneration (130-132). If the network of the two components is disrupted, it is 
thought to lead to the development of CMT. The gene mutation may occur on 
either neurons or Schwann cells, or both of them, which directly or indirectly 
disrupt the cell-cell interactions (133). In addition, defects in axonal transport 
are commonly seen in CMT, because neurons in PNS are more sensitive to 
these defects considering the length of the axons (134). Table 1.4 and Figure 
1.8 demonstrate the gene mutations and protein defects on the Schwann cell 
that lead to CMT (135). 
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Figure 1.8. Schematic overview of a myelinating Schwann cell 
highlighting the subcellular localization of proteins mutated in 
demyelinationg peripheral neuropathies and their binding partners (135) 
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Table 1.4 Classification of demyelinating neuropathies and their 
inheritance (135) 
 
There are many forms of CMT disease, including CMT1, CMT2, CMT3, 
CMT4, and CMTX. The most common subtypes will be discussed here. CMT1 
with associated peripheral nervous system (PNS) demyelination is the most 
frequent diagnosis. It demonstrates slowed nerve conduction velocities and 
segmental demyelination upon nerve biopsy(136).    
It was first found the CMT1A was linked to chromosome 17p11.2 
(137-138). Later in 1991, a large segmental duplication about 1.4 Mb of DNA 
was reported in two independent cases (139-140), within which the complete 
peripheral myelin protein22 gene (PMP22) was mapped (141). Consequently, 
defects in PMP 22 are confirmed to cause CMT1A. The duplication of 
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chromosome 17p11.2 is the most common genetic mechanism of CMT1 as it 
is seen in about 70% of all cases of CMT1 (142-143). Later it was reported that 
deleting the same section of chromosome 17p11.2 causes hereditary 
neuropathy with liability to pressure palsies (HNPP), an autosomal-dominant 
condition characterized by episodic recurrent pressure palsies, events of 
paralysis or paresis, at points of nerve entrapment (144). Furthermore, point 
mutations, including missense, nonsense, splice site, and frameshift mutations, 
in chromosome 17p11.2 were also found to cause CMT1A (141,145-147). 
PMP22 is a hydrophobic 22-kDa glycoprotein of 160 amino acids with four 
transmembrane domains mainly expressed by myelinating Schwann cells in 
the PNS. It is only present in the compact myelin and constitutes about two to 
five percent of the total PNS myelin protein (148-149). The function of PMP22 
is not clear yet, but it is proposed that PMP22 may function in the initiation of 
myelin spirals, regulation of growth differentiation of Schwann cells and control 
of thickness and stability of myelin sheaths (150). 
Myelin protein zero (MPZ) is the causative gene for the CMT1B disease, 
which is much less common than CMT1A, accounting for less than five percent 
of all CMT1 (142,151-152). The MPZ gene is located on chromosome 1, 
region q22-q23 (151,153-154). To date, over 125 different mutations in the 
MPZ gene leading to peripheral neuropathy in patients have been reported 
worldwide (http://www.molgen.ua.ac.be/CMTMutations/default.cfm). The 
distribution of the mutations is illustrated in Figure 1.9 (155). It is found that all 
30 
 
 
mutations resulting in change or deletion of amino acid residues in MPZ give 
rise to neuropathy with the only exception R215L, which instead causes a 
benign polymorphism (156). Furthermore, more detailed analysis classifies the 
MPZ mutations into two major groups (155). In the first group, the mutations 
disrupt the intracellular processing of MPZ and are mainly associated with 
early onset neuropathy(157). It is proposed that the mutated MPZ is trapped 
inside the cell rather than being transported to the plasma membrane. 
However, other evidence suggests that the mutated MPZ protein is expressed 
on the plasma membrane, but disrupts the structure of myelin by a 
dominant-negative mechanism (155,158-159). In the second group, the MPZ 
mutations are associated with a late onset neuropathy since the mutations 
cause only mild demyelination. The underlying mechanism is elusive but the 
current hypothesis is that the mutations cause minor abnormalities in the 
myelin sheath that over time may lead to aberrant Schwann cell-axon 
interactions and subsequently to axonal degeneration(157). Myelin protein 
zero (MPZ), associated with CMT1B, is a transmembrane protein of 219 amino 
acid residues. Human MPZ consists of three domains: 125 residues constitute 
the glycosylated immunoglobulin-like extracellular domain, 27 residues span 
the membrane, and 67 residues represent the highly basic intracellular domain 
(160-161). MPZ, a homophilic adhesion molecule(162-164), is a member of 
the immunoglobulin super-family (165) and is essential for normal myelin 
structure and function. It is proposed that MPZ forms homotetramers, a 
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doughnut-like structure with a hole, and interacts with the opposite 
homotetramer with a head-to-head interaction (166). In vivo the MPZ knockout 
mice displayed abnormal myelin that severely affects the myelination 
pathway(167), and overexpression of MPZ causes congenital hypomyelination 
of peripheral nerves(168). The cytoplasmic domain of MPZ is also necessary 
for the proper adhesion function (169). 
CMT1C is linked to chromosome 16p13.1 (170) and mutations in the 
lipopolysaccharide-induced TNF factor gene (LITAF gene) (171-173). Six 
mutations have been found to cause CMT1C. It is suggested that the LITAF 
sequence may be involved in the ubiquitin-mediated proteosome pathway and 
interactions with other proteins via the PPXY and the PSAP motifs (173).  
CMT1D contains mutations in the early growth response 2 (EGR2) gene 
on chromosome 10q21-22 (174). ERG2, a zinc finger transcription factor, is 
critical in PNS development (175). Consequently, even before the onset of 
PNS myelination, the EGR2 gene is expressed in mice and rats (176). The 
regulatory functions of EGR2 include the expression of PMP22, MPZ, gap 
junction protein β1 and Periaxin, and the synthesis of lipids (177-179). 
CMT2E is linked to mutations in the neurofilament protein, light 
polypeptide gene (NEFL), that cause reduced nerve conduction velocities, 
axonal degeneration, and the presence of small onion bulbs. NEFL is located 
within the cytoskeleton of myelinated axons. Neurofilaments (NF), structurally  
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Figure 1.9 Mutations on the open reading frame of MPZ (155).  
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and functionally important for axons, are composed of three neuron specific 
proteins: NEFL 68kD, NF medium 125 kD and NF heavy 200 kD on SDS 
polyacrylamide gels (180-181).  
In addition, CMTX, an X-linked form of CMT, arises from a mutation in 
the connexin-32 gene(182).
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CHAPTER 2: MATERIAL AND METHODS 
2.1 Plasmid purification and characterization 
The plasmids were transformed into DH5α E. coli and plated on LB plates 
in the presence of the antibiotic, ampicilin, as a selective agent. Then a single 
colony was selected and inoculated into liquid LB medium with the selective 
agent. The culture was keep at 37 ºC with shaking. The plasmids were purified 
with a MiniPrep purification kit (Invitrogen). The DNA concentration of the 
purified plasmids was determined as a function of absorbance at 260nm. The 
DNA purity was determined by the ratio of A260nm/A280nm. The plasmids were 
cut by restriction enzymes and the DNA was sequenced. Aliquots of the 
plasmids were prepared and stored at -80 degrees to avoid freeze and thaw 
cycles and to prevent potential degradation. 
2.2 Agrarose gel electrophoresis 
The agrarose gel electrophoresis was carried out with the HOEFER mini 
DNA electrophoresis apparatus and 0.8 to 1.0 grams of agarose that was 
dissolved in 100 ml TAE buffer and heated in a microwave for one to two 
minutes. After the melted agraose had cooled to 50 degrees, ethidium bromide 
was added for DNA staining. The melted agraose solution was poured into the 
electrophoresis apparatus. The sample loading wells were made by using a 
comb with tooth dimensions of 1.5 mm thickness and 5 mm width.  
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DNA samples were mixed with BlueJuice loading buffer (65% sucrose, 10 
mM Tris-HCl, pH 7.58, 10 mM EDTA, 0.3% Bromophenol blue).  
The gel was run at 10V/cm for one to two hours until the dye reached 
about one centimeter from the bottom of the gel. The electrophoresis pattern 
was viewed on a short wave ultraviolet transilluminator to visualize the DNA 
stained with ethidium bromide. 
2.3 E. coli. transformation 
The plasmid (50ng) and competent cells (50 µl) were mixed and incubated 
on ice for ten minutes to achieve maximal contact between the plasmids and 
competent cells. The E.coli–DNA mixture was heat shocked at 42ºC for 20 
seconds. The E.coli–DNA mixture was kept on ice for two minutes to reduce 
potential damage to the competent cells. LB liquid medium (950 µl) without the 
antibiotic was added to each tube and incubated at 37 ºC for one hour. Then 
the liquid culture was spread on two LB plates containing the antibiotic using 
200 µl and 800 µl culture respectively. The Petri dishes were grown overnight 
at 37 ºC to obtain isolated single colonies. 
2.4 Protein expression, purification, and dialysis 
The conditions for protease expression, purification and dialysis were 
highly similar between the inactive and active MDR769 HIV-1 protease. The 
only difference is the pH value of the buffer at the ionic exchange 
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chromatography step. The buffer pH of the inactive protease preparation is 8.6, 
and the pH of the active protease preparation is 7.8. Sections 2.4.1 and 2.4.2 
describe the preparation of the inactive and active HIV-1 MDR protease.    
2.4.1 Inactive MDR769 HIV-1 protease  
The inactive MDR769 HIV-1 protease A82T was over expressed by using 
a T7 promoter expression vector in conjunction with the E. coli host, BL21 
(DE3). In brief, a fresh transformant of BL21 (DE3) with the MDR769 plasmid 
was cultured in 5 ml LB medium containing 100 mg/ml ampicillin for 7 hours, 
which was used to inoculate 50 ml LB medium containing 100 mg/ml ampicillin 
overnight. Later, the culture was inoculated into two liters of LB medium with 
100 mg/ml ampicillin to an to an absorbance at 600nm of 0.1. After 4 to 6 hour 
of incubation with shaking at 37ºC, the A600 was increased to 0.5 and these 
cells were harvested at 10,000xg for 10 min at 4ºC by using a Sorvall RC5B 
Plus centrifuge (183). The inactive MDR769 HIV-1 protease was isolated from 
inclusion bodies by using a series of buffered washes, followed by denaturing 
in 6 M urea. For purification of the unfolded protease, an anion exchange resin 
with pH 8.6 (Q Sepharose, Amersham Biosciences) was used that allowed the 
protease to pass through and the contaminants to bind. The protease was 
determined to be purified greater than 95% through Coomassie blue-stained 
SDS-PAGE (184).The 6M urea was removed to refold the protease by using a 
series of dialysis exchanges that were carried out at 4ºC. The first buffer 
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consisted of 0.2M sodium phosphate monobasic, 0.2M sodium phosphate 
dibasic, 1.0M urea, 0.2% βME, and 10% glycerol. The next three buffer 
changes consisted of 0.2M sodium phosphate monobasic, 0.2M sodium 
phosphate dibasic, 0.2% βME, and 10% glycerol. The last two buffer changes 
were 10 mM sodium acetate, 1 mM DTT and 10% glycerol (pH 5). The 
protease was concentrated by Amicon to between 2 and 3 mg/ml for storage at 
-80ºC in aliquots. Figure 2.1 shows the SDS gel of MDR769 HIV-1 protease. 
 
 
Figure 2.1. SDS PAGE gel of MDR769 HIV-1 protease after ion exchance 
column at pH 8.6. The left column was the size market. The bands on the right 
were the denatured inactive MDR769 HIV-1 protease around marker level of 10K Da. 
The fractions with pure protein were collected, pooled together and subjected to 
dialysis in order to remove the urea and refolded the protein. 
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2.4.2 Active MDR796 HIV-1 protease 
The active MDR769 HIV-1 protease was over expressed by using a T7 
promoter expression vector in conjunction with the E. coli host, BL21 (DE3). In 
brief, a fresh transformant of BL21 (DE3) with the active MDR769 HIV-1 
protease plasmid was cultured in 5 ml LB medium containing 100 mg/ml 
ampicillin for 7 hours, which, in turn, was used to inoculate 50 ml LB medium 
containing 100 mg/ml ampicillin overnight. Later the culture was inoculated to 
two liters of LB medium with 100 mg/ml ampicillin to an A600 of 0.1. After 4 to 
6 hour of incubation with shaking at 37ºC, the A600 had increased to 0.5 and 
these cells were harvested at 10,000xg for 10 min at 4ºC by using a Sorvall 
RC5B Plus centrifuge (183). The active MDR769 HIV-1 protease was isolated 
from inclusion bodies by using a series of buffered washes, followed by 
denaturing in 6 M urea. For purification of the unfolded protease, an anion 
exchange resin with pH 7.8 (Q Sepharose, Amersham Biosciences) was used 
that allowed the protease to pass through and the contaminants to bind. The 
protease was determined to be purified greater than 95% through Coomassie 
blue-stained SDS-PAGE (184).The 6M urea was removed to refold the 
protease by using a series of dialysis exchanges that were carried out at 4ºC. 
The first buffer consisted of 0.2M sodium phosphate monobasic, 0.2M sodium 
phosphate dibasic, 1.0M urea, 0.2% βME, and 10% glycerol. The next three 
buffer changes consisted of 0.2M sodium phosphate monobasic, 0.2M sodium 
phosphate dibasic, 0.2% βME, and 10% glycerol. The last two buffer changes 
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were 10 mM sodium acetate, 1 mM DTT and 10% glycerol (pH 5). The 
protease was concentrated by Amicon to between 2 and 3 mg/ml for storage at 
-80ºC in aliquots. 
2.4.3 Extracellular domain of human wild type myelin protein zero 
The extracellular domain of the wild type human MPZ (hP0ex) was cloned 
into pMAL™-p2X vector (New England Biolabs), at the XmnI/XbaI sites. The 
insertion of hP0ex downstream from the malE gene, which encoded the 
maltose binding protein (MBP), resulted in a translational fusion of the E.coli 
MBP to the N-terminus of hP0ex. To facilitate protein crystallization, a flexible 
triple alanine linker was inserted between the MBP and hP0ex. This 
polyalanine linker allowed the MBP and hP0ex domains to fold independently. 
Also, in recent reported crystal structures, the presence of MBP did not disturb 
the 3D structure of the target protein in crystals (185-187). In addition, the 
structures of both apo-MBP (188) and maltose-bound forms (189-190) have 
been determined and could be employed as search models to solve the phase 
problem. 
E. coli BL21 (DE3) cells were transformed with the MBP-hP0ex fusion 
plasmid, and the cells were grown in LB medium supplemented with ampicillin 
(100µg/ml) at 37oC to a cell density of OD600 = 0.5. Fusion protein expression 
was induced with isopropylthiogalactoside (IPTG) for two hours. Cell lysates 
were prepared, and the fusion protein purified twice by amylose-sepharose 
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affinity chromatography (191). The final protein was concentrated to 5.0 mg/ml 
in buffer of 20 mM Tris, pH 8.0, 200 mM NaCl, and 1 mM EDTA. The gel 
pattern is shown in Figure 2.2 
2.5 Crystallization 
2.5.1 In-house crystallization screening 
The inactive MDR769 HIV-1 protease variants with concentration 1.5 to 
2.5 mg/ml were subjected to centrifugation to remove insoluble impurities. The 
hanging drop vapor diffusion method was used to form the bipyrimidal crystals 
of the inactive MDR769 HIV-1 protease. Using a matrix screen consisting of 
pH values (5.5 to 8.1) versus sodium chloride (0.7 to 1.4 M), the HIV-1 
protease-substrate complex crystals were formed overnight at 22 ºC. Routinely, 
0.2 mm crystals in the longest dimension were obtained after 14 days of 
incubation. In each well, there were two droplets, containing 1µl of protein, 1µ 
of reservoir solution and 2µl of protein, 1µ of reservoir solution respectively. 
The later combination was adopted to increase protein sample concentration 
to facilitate the crystallization. 
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Figure 2.2. The SDS PAGE gel of MBP-hP0ex fusion protein. The red arrow 
indicates the band of MBP-hP0ex fusion protein. Column A was the initial pool of 
MBP-hP0ex fusion protein after the first amylose-sepharose affinity chromatography 
and it was not pure enough. The second amylose-sepharose affinity chromatography 
gave columns 3, and 5 to 8, which were pooled together to get pure MBP-hP0ex 
fusion protein. 
 
42 
 
 
 
2.5.2 High-throughput crystallization screen (HTS) 
Protein samples were sent to the Hauptman-Woodward Institute (HWI) for 
high throughput crystallization screening experiments using the batch method 
(1536-well micro assay plates)(192). We optimized the initial crystallization hits 
with the hanging-drop vapor diffusion method in the lab. The best crystals 
(hP0ex) were grown from 40% PEG 8000, 0.1 M KSCN, 0.1 M Tris, pH 11.1. 
Needle shaped crystals of MBP-hP0ex fusion protein appeared within one 
week at 22 ºC. The crystals were soaked for two minutes in 30% glycerol and 
flash frozen for diffraction experiments. 
Figure 2.3 shows the original crystallization hit from HTS and Figure 2.4 
represents the crystals after condition optimization. 
2.5.3 Cryoprotection of crystal 
To protect the crystal from cracking when fresh frozen, two different 
cryoprotectents were used. 30% glucose (W/V) and 30% glycerol (v/v) were 
used respectively for HIV-1 protease and myelin protein zero crystals. Fresh 
cryoprotectent was made before flash freezing the crystals. One drop of the 
cryoprotectent was placed on a clean slide into which a harvested crystal was 
immensed for about 30 seconds. The crystals were harvested with CyrstalCap 
HT(Hampton Research), a complete crystal mounting system for manual and 
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automated cryocrystallography, and were stored with aluminum CryoCanes 
(Hampton Research) in liquid nitrogen.  
Figure 2.3 Hit from high-throughput crystallization screen showing 
crystals of the the extra-cellular domain of wild type human myelin 
protein zero. The crystals of the extra-cellular domain of wild type human myelin 
protein zero in the leading crystallization condition hit from the high-throughput 
crystallization screen at Hauptman-Woodward Institute (HWI) using the batch method. 
The leading hit condition was 20% PEG 8000, 0.2 M KSCN, 0.1 M Tris, pH 9. 
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Figure 2.4 The crystals after in-house condition optimization with the 
hanging drop method based the leading HTC crystallization condition 
hits. Individual needle shape crystals were harvested and frozen for data collection. 
The crystallization temperature was at 22 oC and the condition was 40% PEG 8000, 
0.1 M KSCN, 0.1 M Tris, pH 11.1. 
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2.6 Crystal diffraction data collection 
Data were collected from a single crystal at the Advanced Photon 
Source (APS) (LS-CAT 21), Argonne National Laboratory (Argonne, IL). The 
beamline used was 21-ID-D with MD-2 diffractometer hardware and software 
from EMBL for sample mounting, centering, beamline diagnostics, and data 
collection. The detector was a Mar 300 CCD. Raw data were reduced with 
program HKL2000.  
 
2.7 Diffraction data analysis 
2.7.1 CrystalClear 
CrystalClear is a program provided by Rigaku Americas Corporation. It 
incorporats the concept that data acquisition and data processing should be 
combined under one common, modern interface called d*TREK, a powerful 
compute engine designed to process data from all Rigaku detectors including 
those at synchrotrons. As a result, it provides a complete graphical user 
interface for data collection and processing, which includes instrument control, 
data collection, data collection strategy, data processing, image viewing, 
manipulation tools, and, continuous instrument and processing analysis 
modules. In the data collection module, there were functions such as 
integration, empirical and numerical absorption corrections, scaling and 
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calculation of ESDs, Laue group and space group determination and 
reciprocal lattice viewer.  
 
2.7.2 HKL2000 
HKL2000 was also used to reduce the diffraction data. The HKL-2000 
program package was based on the extended versions of Denzo, Xdisplayf, 
and Scalepack. Similar to CrystalClear, it also employs a graphical user 
Interface. HKL2000 is a new, extended and significantly improved version of 
the HKL-package that includes all the features of HKL plus major new options, 
such as 3-D processing, that improve the integration of data from crystals with 
very high mosaicity. It also processes data collected with any spindle axis 
orientation and refines the direction of the spindle axis. The absorption 
correction dramatically improved the anomalous signal. ???? 
2.7.3 CCP4 
The Collaborative Computational Project Number 4 in Protein 
Crystallography was set up in 1979 to develop a comprehensive collection of 
software for crystallography.  
For the HIV protease drug resistance project, molecular replacement was 
performed with Molrep-autoMR in CCP4 (193) with the model previously solved 
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in our lab (194). Initial refinements were performed by Refmac5 (195-196). The 
models were further built according to the electron density maps in program 
COOT (197) as the refinement processed. Crystallographic solvent water was 
added in program ARP/wARP(198). The structures were refined to the final 
resolution in Refmac5. The final stereochemical parameters were checked 
using PROCHECK(199). B factor analysis was done by program Temperature 
Factor Analysis in CCP4. Structure superpositions and their corresponding 
RMSD values were calculated with the CCP4 program Superpose Molecules 
(200). Protease superpositions were based upon the Cα  atoms of residues 1 
through 99.. 
In the MPZ structural project, CCP4 suite(193) was used to convert .sca file 
to .mtz file. Molecular replacement was performed by Molrep-autoMR to get 
phase information(195) in CCP4 suite of programs with the maltose binding 
protein model 1ANF and rP0ex model 1NEU(166,190). The maltose molecule 
was built into the difference electron density maps in the COOT program(197). 
Solvent water was added using ARP/wARP program(198). The structures were 
refined to resolution 2.1 Å in Refmac5. The final stereochemical parameters 
were checked using PROCHECK(199), 
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2.7.4 COOT 
The Crystallographic Object-Oriented Toolkit (COOT) is a convenient tool 
for macromolecular model building, model completion and validation. It also 
displays maps and models and allows model manipulations such as 
idealization, real space refinement, manual rotation/translation, rigid-body 
fitting, ligand search, solvation, mutations, rotamers, Ramachandran plots, 
skeletonization, non-crystallographic symmetry and more. 
2.7.5 PyMol 
PyMol is a molecular visualization system created by Warren Lyford 
DeLano and commercialized by DeLano Scientific LLC. It is a powerful tool for 
producing high quality three=dimensional images of both small molecules and 
biological macromolecules.  
2.7.6 PISA Server 
PISA is an acronym for protein interfaces, surfaces, and assemblies. It is 
an interactive tool that analyzes macromolecular interfaces, predicts probable 
quaternary structures, and searches the PDB and other databases for 
structurally similar interfaces. Pisa Server was used to calculate the dimer 
interface of MDR769 HIV-1 protease variants (201).  
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2.8 Protease enzyme assays 
The active MDR769 HIV-1 protease produced in our lab and the WT HIV-1 
protease (NL4-3), purchased from AnaSpec, were cryo-protected by 50% 
glycerol and stored at -20 ºC.  The fluorescent substrate (FRET substrate I) 
which mimicked the natural substrate peptide MA/CA with excitation/emission 
wavelength 340/490 nm respectively was dissolved in DMSO at a 
concentration of 500 µM (202-203). The composition of the fresh enzyme 
buffer was 0.1 M sodium acetate, 1.0 M sodium chloride, 1.0 mM 
ethylenediaminetetraacetic acid (EDTA), 1.0 mM dithiothreitol (DTT), 10% 
dimethylsulfoxide (DMSO), 1 mg/ml bovine serum albumin (BSA), and the pH 
was adjusted to 4.7.  The ligand was dissolved in DMSO at a concentration of 
20 mM and stored at -20 ºC. It was diluted on a two-fold series (the first 
concentration is two fold higher than the next one) before enzyme assay.  
A 96 well flat bottom assay plate was used for the assay. A SpectraMax M5 
from Molecular Devices was used to read the fluorescent signal and SoftMax 
Pro was used to plot and analyze the data.  
In each well of the assay plate, 97 µl of enzyme buffer was added first. 
Then, 1 µl of one of the proteases was added to the buffer to make the final 
concentration 20 µM. 1 µl of ligand at different concentrations was then added 
to the system. The whole system was mixed gently and incubated at 37 ºC for 
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ten minutes. 1 µl of fluorescent substrate was added to make the final 
concentration of 5 µM. The fluorescence signal was read at one minute 
intervals for twenty minutes at 37 ºC. The IC50 value were calculated with the 
program SoftMax Pro.  
The fluorogenic substrate used in the enzyme assay was purchased from 
AnaSpec. It is a MA/CA substrate peptide analog with the sequence 
DABCYL-GABA-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-EDANS; this peptide is also 
referred to as HIV protease substrate I. It was widely used for the continuous 
assay for HIV protease activity. Upon the cleavage of the substrate, the 
EDANS molecule fluroresces at 490nm wavelength after excitation at 340 nm.  
This emission is quenched by nearby DABCYL in the uncleaved substrate.  
As a result, the experiment demonstrated a time-dependent increase in 
fluorescence intensity that was linearly related to the extent of substrate 
hydrolysis.  
2.9 Chemical synthesis 
The Abbott protocol was adopted to synthesize the library of lopinavir 
analogs as shown in Figure 2.5 and Figure 2.6 (204). A hydroxylethylene core 
consisting of the P1 and P1’ residue was synthesized first. Next, the P2 and 
P2’ residues were added to the core to obtain the final desired molecule by a 
regular peptide bond coupling. The amine and carboxylic groups of 
L-Phenylalanine, the starting material of the hydroxylethylene core, were 
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protected with benzyl groups in step1 to obtain a benzyl ester. In step 2, the 
carboxyl group was deprotected to synthesize the nitrile from the ester. In step 
3 the Grignard reaction was carried out where the P1 residue was attached to 
the core. At this point the core was a keto-enone and needed to be further 
reduced to obtain the final hydroxyethylene core. In step 4, a reduction 
reaction was used to obtain the hydroxyl group between the P1 and P1’ 
residues. Enantiomers were produced in the reaction and then separated on a 
silica column to get the desired pure isomer (done by our collaborators). In 
step 5, the free amine group was protected and the remaining benzyl groups 
were removed. In step 6, the P2’ residue (acid1) was coupled to the free amine 
group of P1’ residue. In step 7, the Boc protection was removed and the P2 
residue (acid3) was coupled to the free amine group of the P1 residue. In my 
experiment, P1 site is the side chain of Phenylalanine and P1’s site is the side 
chain of Homo- Phenylalanine. The supporting documents (MS analysis 
results of the reaction intermediate) for each reaction are shown in the 
appendix.  
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Figure 2.5 The synthetic scheme of lopinavir analog. This synthetic scheme 
was adapted from the Abbott protocol. The hydroxylethylene core was synthesized in 
the lab with the desired modifications on the P1 and P1’ sites of lopinavir. Four 
stereoisomers were produced after the step 4, which require further purification. The 
core then was coupled with prepared acid 1 and acid 3 to yield the final product of a 
lopinavir analog.  
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Figure 2.6 Proposed library of lopinavir analogs. The green color, red color, 
blue color and purple color represents the P2, P1, P1’ and P2’ of lopinavir respectively. 
P2 and P2’ were kept the same as the original lopinavir. P1 and P1’ underwent 
different modifications to restore the binding affinity of lopinavir to MDR HIV-1 
protease. This figure listed part of the proposed library considering the tremendous 
combination of different modifications. The first four lopinavir analogs show the 
modifications at P1’s site, while the last four lopinavir analogs contain 
modification in P1 site.  
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2.10 Construction of protease – substrate models 
2.10.1 Construction of wild type HIV-1 protease – substrate 
(Gag-Capsid) model 
For the substrate, we used the NMR (nuclear magnetic resonance 
spectroscopy) based solution structure of a large protein, the MA4CA sub 
domain of Gag that includes the C-terminus last four residues 
(Ser-Gln-Asn-Tyr) of Matrix and full length CA totaling 150 residues. We 
superposed the Cα atoms of P2'-P1'-P1-P2 residues from MA4CA onto the 
equivalent peptide substrate residues of the crystal structure, 1KJ4 (205), with 
a root mean square (RMS) delta of 0.4 Å using the LSQKAB from the CCP4 
(193) suite of programs. We then replaced the peptide coordinates in 1KJ4 
with the substrate, MA4CA as shown in Figure 2.7 to construct the wild type 
protease with substrate docked into the active site cavity. 
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Figure 2.7 Modeling the Gag-Capsid substrate into the active site cavity 
of HIV-1 protease. The N-terminus of the NMR structure of Capsid (shown in yellow 
on the left) with MA/CA cleavage site sequence (SQNY/PIV) was superposed onto the 
corresponding residues in the heptapeptide taken from the crystal structure 1KJ4 
(wild type protease in complex with the MA/CA cleavage site heptapeptide). The 
Capsid was then docked into the active site cavity of the wild type protease by 
replacing the peptide coordinates in 1KJ4 to obtain the final model shown on the right. 
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2.10.2 Construction of MDR769HIV-1 protease – substrate 
(Gag-Capsid) model 
Mutation N25D was introduced in the 1TW7 (206) crystal structure in both 
chains of the MDR protease dimer prior to the substrate docking. Both the 
catalytic aspartates were unprotonated to represent physiological pH in wild 
type as well as MDR models. The substrate was then docked into the 
expanded active site cavity of the MDR protease by superposing the MDR 
protease onto the wild type protease-substrate model. Residues 1 to 7, 24 to 
29 and 95 to 99 were chosen for superposing the MDR protease onto the 
corresponding Cα atoms of the wild type protease in the model. The 
coordinates for the substrate from the wild type HIV-1 protease-substrate 
model were then copied into the MDR769 coordinate file. Both the initial 
models showed multiple steric clashes of the substrate with the protease flaps 
(Figure 2.8 ) indicating the requirement of major conformational changes in the 
protease flaps before substrate docking. 
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Figure 2.8 Initial models of the protease-substrate complexes. Shown in 
green is the wild type HIV-1 protease taken from 1KJ4 and in red is the MDR769HIV-1 
protease taken from 1TW7, both docked with the substrate (Gag-Capsid shown in 
yellow) into their active site cavities. Both models show multiple steric clashes with the 
protease flaps 
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2.11 Molecular dynamics simulations 
The apo-protease structures taken from 1TW7 and 1KJ4 (peptide 
coordinates were deleted) were initially subjected to a 5 nano second MD 
simulations. All MD simulations were run using the GROMACS (207) package 
with the GROMOS96 force field at a temperature of 300 K and a pressure of 1 
bar. The temperature and pressure were loosely coupled using Berendsen's 
procedure. Crystallographic waters were deleted from all the starting 
structures and the final models were solvated with the SPC (single point 
charge) (208) water model. Long range electrostatics was incorporated using 
the PME (particle mesh Ewald) method with a 9 Å cutoff. After 5 nano seconds 
of MD, the substrate was docked into the active site cavity and both the 
models (wild type protease-substrate complex model and MDR 
protease-substrate complex model) were then further subjected to a 5 nano 
second MD simulation using the protocol described earlier. 
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CHAPTER 3: CRYSTAL STRUCTURE OF FOUR MDR769 HIV -1 
PROTEASE VARIANTS 
3.1 Introduction 
3.1.1 Wild type HIV-1 protease 
HIV-1 protease is a homodimeric, aspartic protease that is critical for the 
viral maturation (209) and infectivity (210). Each monomer of the protease 
consists of 99 amino acids. Because disabling the protease would significantly 
slow down the viral infection, HIV-1 protease has become one of the most 
important drug targets to design inhibitors to combat the HIV/AIDS problem. 
Error prone viral replication randomly incorporates multiple mutations resulting 
in the emergence of multidrugresistant strains under the selection pressure of 
various treatment regimens. HIV-1 protease is one of the viral proteins that 
have been studied in detail to understand the affect of various mutations.  
3.1.2 Crystal structures of WT and MDR HIV-1 protease 
It is very important to study the structures of apo-protease to understand 
the overall stability of the protease dimer as well as the conformational state of 
various critical domains of the protease such as flaps, 80s loops (Pro79 – 
Ile84) and active site cavity. As shown in Table 3.1, there is a plethora of 
structures of HIV-1 protease variants (194,206,211-218), but only two crystal 
structures of MDR apo-protease strains (showing altered flap conformation) 
from a total of twelve structures of apo-protease are available to date. The first 
medium and high resolution crystal structures of a clinical isolate MDR769 
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HIV-1 protease with a wide-open conformation of the flaps was reported by our 
group and the second structure of an MDR strain with such open conformation 
of flaps was reported by another group.  
 
Table 3.1 List of currently available HIV-1 protease apo-protein structures 
 
3.1.3 Mutations in HIV-1 protease gene 
Among the mutations seen in the wild type HIV-1 protease gene, 32.32% 
are constituted by the natural polymorphisms (NP) (shown in Figure 3.1a). 
Such NPs are observed in the strains isolated from the treatment naïve 
patients. Once the patients are started on specific treatment regimens during 
the HAART (Highly active anti-retroviral therapy), the drug resistant strains of 
protease are selected clinically. Depending on the combination cocktail used in 
the HAART, some patients might eventually get selected for the MDR strains 
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of the protease. Analysis of the drug resistance mutations (DM) from the 
Stanford HIV database, revealed that, based on more than 4000 clinical 
isolates, the DMs constitute 60.60% of the protease gene. Frequency 
distribution of such NPs and DMs analyzed from the Stanford HIV database is 
shown in Figure 3.1b. With more than 50% of the gene prone to DMs, 
designing inhibitors against such a drug target can be hypothetically compared 
to shooting a moving target.  
3.1.4 Multi-drug resistant 769 HIV-1 protease 
The MDR769 HIV-1 protease is one such challenging strains of the HIV-1 
protease that resists almost all the protease inhibitors available to date in the 
HAART. The MDR769 HIV-1 protease consists of a set of ten mutations in the 
protease gene out of which all ten are known DMs and four out of the ten are 
NPs (Figure 1a). Mutations, such as V82A and I84V due to a change from 
longer side chain to short side chain, cause an overall expansion of 3 Å in the 
active site cavity resulting in the loss of contacts with the inhibitors. In addition 
to the active site expansion, due to the conformational rigidity acquired by the 
MDR HIV-1 protease from other mutations, the flaps show a wide-open 
conformation with an inter-flap distance (measured between the Cα atoms of 
Il50 on either flaps) of 12.25 Å (twice that of the wild type protease). In 
combination, the expanded active site cavity and the wide-open flaps cause a 
highly unstable binding of the inhibitor. Thus, the MDR strain is propagated 
further even in the presence of most potent inhibitors. 
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Figure 3.1 Mutations in the HIV-1 protease gene. (a) Amino acid sequence of 
wild type (NL43) HIV-1 protease aligned with isolate from treatment naïve patients 
showing the natural polymorphisms (green), the MDR769 clinical isolate (red) and 
isolate from patients that received treatment showing drug resistance mutations 
(brown). (b) Frequency distribution of various natural polymorphisms (blue plot) and 
drug esistance mutations (red plot) in the HIV-1 protease gene. Mutation frequency on 
y-axis is plotted against the amino acid sequence of the HIV-1 protease. 
 
3.1.5 Variants of multi-drug resistant 769 HIV-1 protease 
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The current study focuses on understanding the affects of additional point 
mutations on the MDR protease structure with MDR769 background 
(consisting of the ten characteristic mutations). Figure 3.2 shows the mapping 
of the characteristic MDR769 mutations and the additional point mutations 
further analyzed in this study. There are three reasons to choose these point 
mutations. First, these mutations represent the side chain changes in either 
volume or polarity. Second, these mutations show high possibility in DNA 
random mutations. Third, all these mutations are seen in clinical isolates and 
documented by the Stanford HIV database. 
The active site cavity, flaps, 80s loop and dimerization domains (Figure 
3.2) were mainly analyzed. Nine clinically relevant additional point mutations, 
as summarized in Table 3.2, were selected for further analysis with an 
MDR769 HIV-1 protease background. Out of the nine point mutations, four 
mutants (I10V, A82F, A82S and A82T) yielded diffraction quality crystals. 
Crystallographic analysis of the four structures mainly geared towards 
understanding: (a) the capability of additional point mutations on causing 
further changes in the three-dimensional structure of the MDR769 HIV-1 
protease making the multidrug-resistance problem worse and (b) if there is a 
common conserved trend among the four structures that can be targeted to 
design future inhibitors against an ensemble of the MDR strains.  
Before we obtained the crystals and analyzed the crystal structures of the 
MDR769 HIV-1 protease variants, we proposed that MDR769 HIV-1 protease 
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represents the end stage form of the HIV-1 protease. As we already know, two 
independent phenomena contribute the most to the drug resistance of 
MDR769 HIV-1 protease. One is the wide open flaps, and the other is the 
expanded active site cavity of the MDR769 HIV-1 protease. Both of the two 
structural changes make the MDR769 HIV-1 protease incapable of holding 
inhibitors stably and tightly in its active site cavity. The extent of the structural 
changes determines the severity of the drug resistance. Larger flap distance 
and larger active site cavity give rise to more drug resistance. As a result, if 
additional mutations introduced to the MDR769 HIV-1 protease fail to further 
open the flaps or to further expand the active site cavity, it indicates that the 
conformation of MDR769 HIV-1 protease is the most resistant form of HIV-1 
protease against FDA approved HIV-1 protease inhibitors and thus the end 
stage form of the HIV-1 protease. On the other hand, if the additional 
mutations further open the flaps and enlarge the active site cavity of MDR769 
HIV-1 proteaes, then MDR769 HIV-1 protease is an intermediate toward the 
the most resistant form in the evolution progress. Only the end stage form of 
HIV-1 protease is worth our further investigation considering the extraordinary 
mutation rate of HIV. 
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Figure 3.2 Mapping the MDR769 HIV-1 protease. (a) Crystal structure (PDB 
code: 1TW7) of MDR769 HIV-1 protease showing color coded domains – dimerization 
domain shown in brown, active site area shown in red, 80s loops shown in green and 
the wide-open flaps shown in yellow. (b) The characteristic ten mutations of the 
MDR769 clinical isolate are highlighted in spheres and red spheres are the focus of 
current study. (c) Domain diagram of the MDR769 HIV-1 protease showing the amino 
acid residues that constitute different domains. Color codes are same as in (a). 
Table 3.2 Mutations chosen in the current study 
 
3.2 Results 
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3.2.1 Crystallization results, electron density maps, and 
structure analysis 
From the ten mutants with MDR769 background, only four mutants (I10V, 
A82F, A82S and A82T) yielded diffraction quality crystals (Table 3.2). Mutants 
I10R and I10F did not express adequately and mutants L46I, V54M and V54L 
yielded crystals that diffracted only to low resolution. Crystal structures of 
MDR769 HIV-1 protease variants I10V, A82F, A82S and A82T were solved 
and analyzed as shown in Table 3.3. All the four structures were solved in the 
space group P41212. The asymmetric unit consists of one molecule of the 
protease monomer. Protease dimers for each structure were calculated by 
applying the crystallographic two-fold symmetry. The 2|Fo|-|Fc| electron 
density maps around the mutation area are shown in Figure 3.3a for each 
mutant. Contiguous electron density was seen for all the mutants except for 
A82F, where partial electron density was seen for the side chain of Phe82. As 
shown in Figure 3.3b, the Cα backbone of each mutant was superposed onto 
that of the wild type HIV-1 protease around the mutation area to search for any 
conformational changes. No significant conformational changes were 
observed at the point of additional mutation in each of the corresponding four 
crystal structures. The four crystal structures were further analyzed for 
conformational changes in comparison with the native MDR769 HIV-1 
protease (PDB code: 1TW7). Most of the conformational changes were seen in 
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the flaps and the 80s loops among the four mutants when compared to that of 
the native MDR769 protease. 
3.2.2 The proline switch in the MDR769 I10V mutant HIV-1 
protease 
The crystal structure of the MDR769 I10V HIV-1 protease variant revealed 
unusual alternate conformations of Pro81 (proline switch) with a 3 Å root mean 
square difference of the Cα atom of the two conformations. In the wild type 
HIV-1 protease and MDR769 HIV-1 protease, the Pro81 formed a trans 
peptide bond, while both cis and trans peptide bonds were observed in 
MDR769 I10V mutant due to the Pro81 switch. We are the first group to report 
such a significant conformational change in the 80s loop. The alternate 
conformations of Pro81 are shown in Figures 3.4a (electron density) and 3.4b 
(refined model). Shown in Figure 3.4c is the protease dimer showing the 
conformational change in the 80s loop due to the proline switch. As shown in 
Figure 3.4d, we propose that Leu23, Glu21, Asn83 and Val84 are key players 
in transmitting the conformational ripple effect of the mutation at codon 10 
(with an MDR769 background) to the 80s loop resulting in the proline switch. 
As shown in Figure 3.5a, the intra-monomer distortion is caused by the 
additional 3 Å increase in the distance between the Cα atoms of Ile50 and 
Pro81 within the same monomer. 
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Table 3.3  Crystallographic table of four MDR769 HIV-1 protease variants 
aRmerge= ΣhklΣi|I(hkl)i-{I(hkl)|/ ΣhklΣiI(hkl)i , where I(hkl)i is the intensity of an 
observation and I(hkl) is the mean value for its unique reflection. Summations cover 
all reflections. 
bThe values in the parethesis indicate the highest resolution shell. 
PDB entry 3PJ6 3OQD 3OQA 3OQ7 
Crystal parameters     
Resolution range (Å) 27.66 – 2.25 27.62 – 1.71 27.28 – 2.25 27.23 – 1.71 
Space group P41212 P41212 P41212 P41212 
Solvent content (%) 47 47 47.91 47 
Data processing     
No. of unique reflections 5356 (768) 12231 (1628) 5466 (764) 11367 (1108) 
I/σ(I) b 14.2 (5.3) 26.4 (2.8) 20.3 (4.8) 17.6 (2.5) 
Rmergea (%) 7.4 (24.7) 6.1 (45.9) 7.1 (37.1) 6.0 (36.8) 
Data redundancyc 3.4 (3.4) 11.3 (4.4) 6.4 (6.5) 5.8 (3.0) 
Completeness (%) 97.6 (99.5) 98.9 (93) 99.7 (99.7) 93.1 (65.2) 
Refinement statistics     
No. of reflections used 5099 11591 5196 10806 
Rworkingd (%) 24.3 19.59 20.22 19.5 
Rfreee (%) 30.41 22.81 23.77 22.39 
Mean temperature factors     
Protein 15.82 19.75 26.32 19.59 
Main chains 15.4 18.63 25.8 18.57 
Side chains 16.28 20.98 26.89 20.71 
Waters 8.59 30.61 28 34.49 
R.m.s.d. bond lengths (Å) 0.021 0.013 0.019 0.013 
R.m.s.d. bond angles  1.94 1.34 1.82 1.4 
Ramachandran plot     
Most favored (%) 87.2 96.2 96.2 94.9 
Additional allowed (%) 10.3 3.8 3.8 5.1 
Generously allowed (%) 2.6 0 0 0 
Disallowed (%) 0 0 0 0 
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cNobs/Nunique. 
dRwork= Σhkl|F(hkl)o- {F(hk|/ΣhklF(hkl)o 
eR free was calculated same way as R working, but with the reflections excluded from 
refinement. The R free set was chosen using default parameters in Refmac 5 
 
 
 
Figure 3.3 electron density maps and analysis of four MDR HIV-1 
protease variants (a) Shown in red are the 2|Fo|-|Fc| electron density maps of the 
four MDR769 HIV-1 protease variants contoured at 1.0 sigma for mutants A82T, 
A82S and I10V and 0.7 sigma for A82F. Shown in stick models are the residues 80 to 
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85 for mutants A82F, A82S and A82T and residues 7 to 13 for mutant I10V. (b) The C
α atoms of residues 80 to 85 (for mutants A82F, A82S and A82T shown in white) 
and 7 to 13 (for I10V mutant shown in white) were superposed onto those of the wild 
type HIV-1 protease (shown in green). 
 
 
 
Figure 3.4 The proline switch in MDR769 I10V mutant. (a) 2|Fo| - |Fc| electron 
density map shown in blue for the alternate conformations of the Pro81 in the 
MDR769 I10V HIV-1 protease crystal structure. The black arrow points to the gap 
between the back bones of the two conformations of the Pro81. (b) Stick models of 
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the Pro81 showing the alternate conformations with a 3 Å shift in the Cα atoms of 
the either conformations. Shown in blue is the more stable conformation pointing 
towards active site cavity and the green is relatively less stable conformation pointing 
away from the active site cavity. (c) MDR769 I10V HIV-1 protease dimer with 
alternate conformations of the Pro81 (shown in the inset). Mutation I10V is highlighted 
in pink. (d) MDR769 I10V mutant HIV-1 protease dimer showing residues Glu21, 
Leu23, Asn83 and Val84 highlighted in red color stick models that are key players in 
the transmission of structural changes from codon 10 to the 80s loop. 
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Figure 3.5 The intra and inter monomer distances in I10V mutant. (a) The 
MDR769 I10V HIV-1 protease monomer is shown in cyan color with Ile 50 and Pro81 
highlighted in red. On the left is shown the intramonomer distance (14.96 Å) between 
the Cα atoms of Ile50 and Pro81 within the monomer with regular conformation of 
the Pro81. Shown on the right is the same protease with proline switch where the 
intramonomer distance is 17.13 Å which is greater than 2 Å contributing to the 
distortion of S1/S1’ pocket. (b) Surface diagram of the I10V mutant showing the top 
view looking into the active site cavity (Asn25 and Asn125 highlighted in blue). Shown 
on the left are the van der Waals interactions between the Ile50 (red) of one monomer 
and Pro81 (red) of the second monomer with a distance of 9.31 Å between the Cα 
atoms. Shown on the right is the same structure with the proline switch where the 
distance has increased to 12.33 Å. This change causes unstable binding of the 
inhibitors. 
3.2.3 The flipped-out conformation of Phe82 side chain in the 
MDR769 A82F mutant  
It was hypothesized that a mutation from short side chain to a bulky side 
chain should restore the lost contacts with inhibitors but instead, our crystal 
structure of MDR769 A82F variant showed a flipped-out conformation of the 
Phe82 side chain as shown in Figure 3.6. The electron density for the terminal 
ring portion of the Phe82 side chain was discontinuous indicating a possibility 
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of flexible side chain. No alternate conformations were found for the side chain 
of Phe82 even at 0.7 sigma level contoured maps. 
 
 
Figure 3.6 Crystal structure of the MDR769 A82F HIV-1 protease. (a) Front 
view of the protease dimer with Phe82 shown in red color stick model. (b) Top view of 
the protease dimer looking into the active site cavity. Phe82 is highlighted in red color 
stick model. The Phe82 ring points out of the active site cavity. (c) Side view of the 
protease dimer with Phe82 highlighted in red color stick model to show the 
characteristic flipped-out conformation of the Phe82 side chain. 
3.2.4 The A82S and A82T mutants  
Crystal structures of MDR769 A82S and A82T HIV-1 protease variants 
show that the hydroxyl group on the side chain is pointing away from the active 
site cavity in A82S while it is pointing towards Leu23 in A82T. Due to the Pro81 
side chain next to Thr82 in the A82T mutant, the hydroxyl group of Thr82 is 
repelled away from Pro81 towards Leu23 which is at a farther distance from 
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Thr82. As shown in Figure 3. 7, the introduction of polarity at position 82 
results in the local change of electrostatics of S1/S1’ binding pockets. 
 
Figure 3.7 Electrostatic potential surface diagrams of wild type (PDB 
code: 3HVP) monomer protease compared to that of the MDR769 A82S, 
A82T and A82F mutant protease monomers. The red, blue, green and white 
colors represent the regions that are negatively charged, positively charged, 
uncharged polar and hydrophobic respectively. Mutants A82S and A82T show 
increased polar uncharged regions in the S1/S1’ pockets that cause unstable binding 
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of inhibitors with hydrophobic P1/P1’ groups. The A82F mutant shows similar 
distribution as that of the wild type in the S1/S1’ pocket due to the bulky Phe82 
hydrophobic side chain. 
3.2.5 Dimer interface calculation and analysis 
Crystal structures of all the four mutants were solved as monomers in the 
space group P41212. Crystallographic two-fold symmetry was applied to 
obtain the dimers for each mutant. These dimers are perfectly symmetrical and 
represent the functional biological unit. Calculation and analysis of the dimer 
interface contacts and surface area suggested that all four mutants including 
the native MDR769 show fewer contacts compared to that of the wild type 
protease. As shown in Figure 3.8a, among the four mutants, the I10V and 
A82T show more contacts at the dimer interface compared to that of the native 
MDR769 while mutants A82F and A82S show fewer contacts compared to that 
of the native MDR769. Although all the mutants, including the native MDR769, 
showed similar molecular weight to surface area ratio compared to the wild 
type protease at the dimer interface, the distribution of the surface area was 
found to be different. The wild type and A82F mutant protease dimers showed 
relatively more surface area at the dimer interface (Figure 3.8b). The inter-flap 
distance was calculated between the Cα atoms of Ile50 of either flap for all 
the mutants of WT (pdb code 1KJ4), MDR769, MDR769 I10V, MDR769 A82F, 
MDR769 A82S and MDR769 A82T HIV-1 potease are 6.02 Å, 12.25 Å, 12.09 
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Å, 12.21 Å, 11.17 Å, and 10.35 Å respectively . All the four mutants show a 
conserved trend of wide-open flaps with varying inter-flap distances. The 
overall dimer stability and wide-open flaps were comparable to that of the 
native MDR769 for all the four mutants. 
  
Figure 3.8 Protease dimer interface analysis. (a) Total number of contacts 
made by the atoms at dimer interface for the wild type and MDR mutants. All the four 
mutants including the native MDR769 dimer have relatively fewer contacts compared 
to those of the wild type HIV-1 protease. Among the four mutants, the I10V and A82T 
show relatively more contacts than those of the mutant A82S and A82F. The wild type 
protease dimer is more stable than that of the MDR variants. (b) Surface area at the 
dimer interface is relatively more for the wild type and MDR769 A82F HIV-1 protease 
variants compared to the native MDR769 and the other two mutants. 
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3.3 Discussion 
3.3.1 Expanded active cavity with wide open flaps 
The crystal structures of all the four mutants showed an overall conserved 
trend of expanded active site cavity with wide-open flaps. In the case of the 
I10V mutant, due to the alternate conformation of the Pro81, when the side 
chain is pointing towards the active site cavity, the protease structure looks 
normal and comparable to the native MDR769 HIV-1 protease but when the 
side chain is pointing away from the active site cavity, it exerts conformational 
stress on the 80s loop leading to the distortion of the S1/S1’ binding pocket 
besides. This results in unstable binding of the inhibitors due to loss of 
contacts. This could be one of the most important mechanisms by which 
MDR769 and other MDR clinical isolates are selected during the HAART. The 
MDR769 I10V mutant HIV-1 protease represents the most expanded active 
site cavity reported so far in the literature. The proline switch also causes the 
loss of inter-monomer van der Waals interactions between the flap and the 80s 
loop as shown in Figure 3.5b. In addition to the original expansion of the active 
site cavity of the native MDR769 strain, the I10V mutant with the proline switch 
shows an overall expansion of the active site cavity by 6 Å (Figure 3.5b) 
compared to that of the wild type HIV-1 protease. Loss of inter-monomer 
contacts in combination with the intra-monomer distortions caused due to 
proline switch may also weaken the protease dimer. Protease variants like 
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MDR769 I10V can be very challenging to the most potent inhibitors available 
to date but on the other hand, such variants are lethal to the viral maturation 
unless there are compensatory mutations in the substrate for a productive 
catalysis. 
3.3.2 The flipped-out conformation of Phe82 side chain in the 
MDR769 A82F mutant 
The bulky side chain of Phe82 increases the conformational stress on the 
flexible 80s loop that causes its flipped-out conformation. This unusual 
conformation not only causes distortion in the S1/S1’ binding pockets but also 
may create a pulling affect on the monomers apart resulting in a weaker dimer. 
Such protease variant can pose threat to the most potent inhibitors as well as 
can decrease the viral replication/maturation unless the substrate molecule 
has compensatory mutations to accommodate the distorted active site cavity 
of the protease. 
3.3.3 Hydrophilic changes at the HIV-1 protease S/S1’ binding 
pocket due to the mutations at codon 82 
Crystallographic analysis of MDR769 A82S and A82T structures suggests 
that if residue 82 is mutated from a hydrophobic residue such as Val (wild type) 
or Ala (native MDR769) to a polar residue such as Ser or Thr, some of the 
critical hydrophobic contacts with the inhibitor especially at the P1/P1’ region 
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are disrupted. Considering the architecture of the side chain, since Thr mimics 
Val (wild type protease) more than Ser, the A82T mutant has less distorted 
S1/S1’ pocket compared to that of the A82S mutant. Nevertheless, both 
mutants challenge the hydrophobic P1 and P1’ functional groups of the 
inhibitors with A82S being relatively severe compared to A82T. Thus, the 
decreased hydrophobicity in the S1/S1’ binding pocket together with the 
wide-open conformation of the flaps result in unstable binding of the inhibitors 
leading to drug resistance. Unfortunately protease variants such as the 
MDR769 A82T can be productive in the substrate catalysis aiding successful 
propagation of the MDR strains. 
3.3.4 The clinical significance of the four mutants on HIV-1 
protease 
The clinical significance of the four mutants (I10V, A82F, A82S and A82T) 
was analyzed in detail from the Stanford HIV database. The frequency of 
various DMs seen in a pool of clinical isolates that consist of a representative 
mutation – I10V or A82F or A82S or A82T was analyzed. The A82F mutant is 
associated with at least 8 other DMs based on 177 clinical isolates from 
treated patients. Similarly, A82S and A82T mutations are associated with at 
least 6 and 7 other DMs respectively within their pools of clinical isolates from 
treated patients. On the other hand, the I10V mutation was only associated 
with two other mutations (L63P and L90M) based on 495 clinical isolates (1.5 
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to 5 times the size of the isolate pools for the other three mutants). This 
indicates that the mutation I10V is very potent in inducing drug resistance 
probably by changing the three-dimensional structure of the protease resulting 
in the Pro81 switch. Thus, our current study provides new insights into the 
multidrug resistance mechanisms of MDR strains of HIV-1 protease. 
3.4 Conclusions 
In summary, we have crystallized, solved and analyzed the structures of 
four MDR769 HIV-1 protease variants. Crystal structure of I10V mutant 
showed that mutation at codon 10 causes a conformational ripple affect 
leading to the alternate conformations of Pro81 (proline switch). Crystal 
structures of A82F, A82S and A82T indicate that mutations at codon 82 may 
not necessarily restore the lost contacts and that the decreased hydrophobicity 
of S1/S1’ pockets further causes loss of contacts with inhibitors.  
Based on the four crystal structures presented in this article, we conclude 
that the flexibility caused in 80s loops (either directly due to mutations such as 
A82F, A82S and A82T or indirectly due to mutations such as I10V) not only 
cause loss of contacts with the inhibitors resulting in the multidrug-resistance 
problem but also result in a weaker HIV-1 protease dimer that is functionally 
not as active as the wild type enzyme. However, such protease variants can 
still function when there are compensatory mutations in the substrate cleavage 
site to accommodate the conformational distortions in the protease binding 
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pockets and the active site cavity. This study further helps to understand the 
design of future inhibitors with enhanced potency. 
The MDR769 HIV-1 protaese presents the end stage of the HIV-1 
protease evolution in the respect of drug resistance. All the additional 
mutations fail to increase further the flap distance and to expand further the 
active site cavity. Without further worsening of these two structural elements, 
the MDR769 HIV-1 protease structure is an excellent study target for us to 
investigate the rapidly emerging drug resistance issue of HIV infection. 
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CHAPTER 4: MODELING OF MDR HIV-1 PROTEASE 
GAG-CAPSID (MA/CA) COMPLEXES 
4.1 Introduction 
4.1.1 HIV-1 protease flap distance and drug resistance 
To design the best inhibitors, it is very important to understand the structure 
and dynamics (219-220) of HIV-1 protease involved in binding and cleavage of 
bigger substrates (221). Previously we reported a high-resolution crystal 
structure (206) of multidrug-resistant (MDR) clinical isolate 769 (222) HIV-1 
protease showing an expanded active site cavity (194) and wide-open flaps. 
According to the active site expansion hypothesis, mutations from longer side 
chain residues to shorter side chain residues decrease contact with the 
protease inhibitors (PIs), thereby, decreasing their binding affinity and potency. 
As illustrated in Figure. 4.1, the wild type protease shows semi-open 
(apo-enzyme) (211) and closed (ligand bound) (205) conformations of the 
flaps while the MDR protease shows wide-open flaps. Numerous crystal 
structures of wild type HIV-1 protease (analyzed from the Protein Data Bank 
(PDB)) showed closed, open and semi-open conformations of the protease 
flaps with varying inter-flap distances. The inter-flap distance of the MDR 
protease is roughly 6-8 Å more than that of the wild type protease. All the 
inter-flap distances were measured between the Cα of Ile50 on either flap. To 
date, there is only one another group that has published crystal structures of 
HIV-1 protease variants showing altered conformation of the flaps (218). 
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Figure 4.1 Crystal structures of HIV-1 protease with different flap 
conformations. The wild type (green) protease structures showing closed (PDB 
code: 1KJ4) on the left and semi-open (3PHV) on the right conformations of the flaps. 
The MDR769 HIV-1 protease (red) shows wide-open conformation of the flaps. 
4.1.2 Wide open conformation of MDR769 HIV-1 protease flaps 
This chapter is focused on answering the question, whether the wide-open 
conformation of the flaps in MDR769 HIV-1 is due to the conformational rigidity 
attained by the accumulation of mutations or if it represents one of the 
thermodynamically favorable substrate binding conformations. We 
hypothesized that: (a) if the wide-open conformation of the MDR protease is 
caused by mutation induced conformational rigidity, then the flaps should stay 
open upon energy minimization and/or molecular dynamics (MD) simulations 
(contrary to what is observed in the wild type protease(223)) due to the steric 
hindrance caused by the mutations in the protease gene (or) (b) if the 
wide-open conformation of the MDR protease is representative of one of the 
favorable substrate binding conformations, then the substrate molecule can be 
easily modeled into the active site cavity of the MDR protease without steric 
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clashes with the protease flaps. 
4.1.3 Energy minimization of MDR769 HIV-1 protease and WT 
control 
In order to understand the flap movement in the MDR protease, the crystal 
structure 1TW7 (MDR769 HIV-1 apo-protease) was energy minimized in the 
absence of crystal contacts. 1000 steps of energy minimization showed that 
the flaps of the MDR protease moveed closer towards each other while still 
maintaining an inter-flap distance of at least 10 Å. As a control, we performed 
the same study using wild type (PDB code: 3PHV) apo-protease, which 
showed the normal flap closure with a final inter-flap distance of 4 Å. This 
clearly suggests that the stable wide-open nature of the MDR protease is not 
entirely due to the crystal contacts (224) as reported by other groups (225) 
because the energy minimization was done in the absence of crystallographic 
symmetry atoms. So we reasoned that the wide-open nature of the MDR 
protease could be due to the steric hindrance caused by individual mutations 
or by all the ten mutations (accumulated in the MDR protease gene) in concert. 
These mutations have changed the three dimensional structure of the MDR 
protease permanently such that the MDR protease shows a conformational 
threshold point for flap closure beyond which the conformational rigidity 
hinders the flap closure. 
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4.1.4 Construction of protease – substrate models 
In order to verify if the wide-open nature of the MDR protease represents 
one of the thermodynamically favorable substrate binding conformations, we 
modeled the natural substrate, Gag consisting of the Capsid (CA) domain only 
including the Matrix/Capsid (MA/CA) cleavage site, into the expanded active 
site cavity of the MDR protease and performed MD simulations. Initially we 
have constructed a similar model using wild type protease to use it as a control 
in our MD studies. 
4.2 Results and Discussion 
4.2.1 The characteristic wide-open conformation of the 
MDR769HIV-1 protease flaps 
Our modeling studies revealed that the substrate (Gag-Capsid) could not 
be modeled into the expanded active site cavity of the MDR769 HIV-1 
protease without steric clashes. This indicates that the wide-open flaps of 
MDR769 HIV-1 protease (as is from the crystal structure PDB code:1TW7) are 
not open enough to accommodate a natural substrate and needs at least 
two-fold further opening of the wide-open flaps of the MDR protease. On the 
other hand, the molecular dynamics simulations of the apo-protease structure 
of the MDR protease as well as protease-substrate complex model showed 
that the wide-open flaps of MDR769 HIV-1 protease never close beyond the 
threshold point set by the conformational rigidity of the MDR protease 
structure. Thus, the accumulation of mutations permanently change the 
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three-dimensional structure of the MDR769HIV-1 protease resulting in a steric 
hindrance for the flap closure even in the presence of substrate modeled into 
the active site cavity. This steric hindrance gives the characteristic wide-open 
conformation to the MDR769HIV-1 protease flaps.  
4.2.2 Molecular dynamics simulations show two-fold and three-fold 
opening of the flaps in the MDR and wild type HIV-1 proteases 
Successful crystallographic docking of the substrate (Gag-Capsid) was 
achieved only after simulating the apo proteases until the flaps are completely 
open. As shown in Figure 4.2, the wild type and MDR apo-proteases were 
initially subjected to a 5 ns MD to achieve a completely open conformation of 
the flaps. The wild type protease showed a three-fold opening of the flaps 
compared to its starting structure (IKJ4) and the MDR protease showed a 
two-fold opening of the flaps compared to its starting structure (1TW7). With 
the flaps completely open (inter-flap distance ~ 20 Å) the substrate was 
successfully docked into the active site cavity of both wild type as well as the 
MDR proteases. These protease-substrate complex models were further 
subjected to 5 ns of MD as shown in Figure 4.3. Thus, the wide-open 
conformation of the MDR protease does not represent one of the 
thermodynamically stable substrate binding conformations because; the flaps 
had to open further to accommodate the substrate. 
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Figure 4.2 Substrate docking and the MD simulation method. Shown in red 
is the MDR769HIV-1 protease. On the left, the apo-protease before substrate 
docking, shows an inter-flap distance of 12.25 Å (characteristic wide-open flaps). In 
the middle, the same apo-protease after 5 ns of MD, shows a completely open 
conformation of the flaps with an inter-flap distance of 25 Å. The substrate 
(Gag-Capsid) is then docked into the active site cavity without any steric clashes and 
the enzyme-substrate model is further subjected to a 5 ns MD to obtain the final 
complex model shown on the right.   
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Figure 4.3 Molecular dynamics simulations of the protease-substrate 
complex models. On the left, are shown the substrate (yellow) docked wild type 
(green) and MDR769 (red) HIV-1 protease models without any steric clashes. After 5 
ns of the MD simulations, the same models are shown on the right. Conformational 
changes in the substrate in the wild type protease-substrate model are pointed by the 
blue pointers. 
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4.4.3 Substrate (Gag-Capsid) is less stable in the expanded active 
site cavity of the MDR769HIV-1 protease 
The radius of gyration of the MDR protease-substrate complex model did 
not decrease with time during the MD in comparison to that of the wild type 
protease-substrate complex model as shown in the Figure 4.4 As evident from 
the fluctuating radius of gyration of the MDR protease-substrate complex 
model, the MDR protease failed to form a stable enzyme-substrate complex 
which could result in unproductive catalysis. The loss of stability for the 
substrate modeled into the expanded active site cavity of the MDR protease 
may be due to loss of contacts and uncooperative wide-open nature of the 
flaps. On the other hand, if the substrate has compensatory mutations, may be 
the MDR protease could form a stable enzyme-substrate complex. This 
mechanism of co-evolution (226) has to be further tested and is beyond the 
scope of the current study.  
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Figure 4.4 Radius of gyration of the models during the MD simulation. 
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The radius of gyration (Rg - nano meters) is plotted on the y-aixs against the MD 
simulation time (pico seconds) on the x-axis. During a 5 ns simulation, the wild type 
protease-substrate complex shows a gradual decrease in Rg (shown in panel a) 
indicating an increase in the overall compactness of the model. On the other hand, the 
MDR769 HIV-1 protease-substrate complex shows a fluctuation in Rg (shown in 
panel b) indicating less compactness. 
4.2.4 Conformational changes in the substrate (Gag-Capsid) during 
the MD simulations 
Conformational changes in the substrate (Gag-Capsid) were observed 
during the MD simulations in the wild type protease-substrate complex model 
(Figure 4.5a) but not in the MDR protease-substrate complex Figure 4.5b). The 
substrate modeled into the wild type HIV-1 protease showed a movement of 
13 Å in the Ala96 loop as shown in Figure 4.6. This could be due to the 
alignment or readjustment of the modeled substrate in the active site cavity of 
the wild type protease towards the formation of a successful enzyme-substrate 
complex. On the other hand, such conformational changes were not seen in 
the MDR protease-substrate complex due to the unstable binding of the 
modeled substrate in the expanded active site cavity of the MDR protease. 
92 
 
 
 
 
Figure 4.5 Root mean square deviation of the substrate molecule. The 
substrate docked into the wild type protease shows a significant RMSD at Ala225 
indicating a major conformational change (shown in panel a) while no such significant 
conformational changes were noticed in the case of the MDR769 HIV-1 protease 
model (shown in panel b) 
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Figure 4.6 Conformational changes in the substrate Gag-Capsid docked 
into wild type HIV-1 protease model. Wild type HIV-1 protease (green) – 
substrate Gag-Capsid (yellow) before MD simulations is superposed onto the 
resultant (purple) model after 5 ns of MD. The Ala225 loop shows a movement of 13 
Å. 
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4.2.5 Alignment of the cleavage site between the catalytic aspartic 
acid residues  
The orientation of the cleavage site (MA/CA) in the substrate (Gag-Capsid) 
modeled into the wild type protease active site cavity has changed during the 
MD simulations. In the MDR protease-substrate model, the cleavage site of the 
substrate appeared to be slipped out of the catalytic site. As shown in Figure 
4.7 the substrate cleavage site in MDR protease-substrate complex failed to 
align the substrate cleavage site between the catalytic aspartic acid residues. 
Due to the expanded active site cavity and wide-open flaps of the MDR 
protease, the substrate modeled into the active site cavity was not stable 
enough to re-orient the MA/CA cleavage site towards a productive catalysis. 
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Figure 4.7 Substrate cleavage site alignment in the protease active site. 
Substrate cleavage site Asn-Tyr-/-Pro-Ile orientation before MD run is shown in cyan 
color and the same after 5 ns of MD run is shown in yellow for wild type HIV-1 
protease complex model and orange for the MDR HIV-1 protease complex model. In 
the wild type model, the cleavage site is oriented favorably for efficient catalysis, on 
the other hand, the cleavage site slips out of the catalytic site indicating less efficient 
catalysis in the MDR model. 
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4.2.6 Implication of MDR769HIV-1 protease substrate (Gag-Capsid) 
modeling studies to drug resistance 
Based on our analysis, we report that the conformational rigidity of the 
MDR769 HIV-1 protease, in addition to the expanded active site cavity, 
prohibits formation of a stable enzyme-substrate complex, which would result 
in reduced catalysis. In the case of small molecule PIs, we predict a similar 
behavior where, if the PI is not potent enough to induce closure of the 
wide-open flaps, then that PI is not stable in the expanded active site cavity. 
Due to lost contacts resulting in unsuccessful enzyme inhibition, one can 
expect the emergence of multidrug-resistance. Thus, the MDR769 HIV-1 
protease, due to its conformational rigidity, poses a great challenge to the 
current PIs that are used in HAART and also is a good model to study the 
MDR strains of HIV-1 protease. 
4.3 Conclusions 
In summary, our results supports the hypotheses that the conformational 
rigidity exhibited by the MDR769 HIV-1 protease hinders substrate binding and 
therefore reduces catalysis. These studies have implications for the design of 
potent competitive PIs against the MDR strains of HIV-1 protease as well as 
enhancing the potency of maturation inhibitors (227) such as PA457 (92). In 
addition, this work may have implications in studies related to viral replication 
in the presence and absence of compensatory mutations in the 
substrate-cleavage sites. Based on our findings, we conclude that the 
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conformational rigidity of the MDR769 HIV-1 protease flaps could be one of the 
novel mechanisms for the multi-drug resistance nature of the MDR protease 
and that new approaches are needed for further studies using models like the 
MDR769 HIV-1 protease. 
 
98 
 
 
CHAPTER 5: HIV-1 PROTEASE IC50 MEASUREMENTS WITH 
LIBRARIES OF REDUCED CA/P2 PEPTIDES AND FDA 
APPROVED INHIBITORS 
5.1 Introduction 
5.1.1 Selectivity and specificity of HIV-1 protease 
It was reported that MDR HIV-1 proteases show reduced binding affinity to 
FDA approved protease inhibitors, while they still keep a certain level of 
enzymatic activity that is required for the viability of the virus itself (228-229). 
As a result, the HIV-1 protease is highly specific for its natural cleavage site 
peptides or their analogs (230-231). However, the selectivity of HIV-1 protease 
is not obvious considering the wide variability of its substrate sequences. 
Research has been performed to determine the best substrate for a particular 
peptide sequence through kinetic measurements of hydrolysis of peptides with 
single amino acids substitution at each position (232-234). Poorman et al 
demonstrated that residues at positions P2, P1 and P2’ are critical for the 
cleavage (235). However, later studies indicated that substrate recognition by 
HIV-1 protease was achieved by shape of the substrate rather than the 
sequence (205,236).  
5.1.2 Reduced CA/p2 peptide library 
CA/p2 cleavage site is the rate-limiting step in all the nine substrate 
cleavage (237). HIV-1 protease can catalize the cleavage of as many as nine 
different natural substrates with various catalytic efficiencies. CA/p2 cleavage 
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site is cleaved by HIV-1 protease with the least efficiency compared to other 
eight substrate peptides. As a result, we choose CA/p2 as our study model to 
make a library of the reduced CA/p2 peptide analogs with substitution of one 
amino acid only in each analog. In addition, the P4’ side Met was replaced by 
NorLeucine to avoid the chemical synthetic obstacles. This library of reduced 
CA/p2 analogs are contributed by our collaborator, Dr. Mark Spaller from 
Dartmouth Medical School. The sequences of this reduced CA/p2 peptide 
library is shown in Table 5.1. The comparison between the regular CA/p2 
peptide and reduced CA/p2 peptide is shown in Figure 5.1. We measured the 
IC50 of this library to both MDR769 HIV-1 protease and WT HIV-1 protease. 
Similar studies were conducted by Altman et al on RT/RH analogs with 
computational and thermodynamics techniques (238). 
5.1.3 HIV-1 protease inhibitors 
Similarly, the IC50 values of six FDA approved inhibitors against both 
MDR769 HIV-1 protease and WT HIV-1 protease were measured to determine 
the extent to which these inhibitors were resistant.  
An HIV-1 protease inhibitor is one of the components of HAART. Currently, 
there are ten FDA approved HIV-1 protease inhibitors on the market. Most of 
these drugs contain a hydroxyethylene core and are peptidomimetic 
competitive inhibitors against the HIV-1 protease by mimicking the natural 
substrates (239-246) . Tipranavir, though, has a dihydropyrone ring as a 
central scaffold rather than a peptidomimetic hydroxyethylene core (247). 
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We have six of all the FDA approved HIV-1 protease inhibitors in our lab, 
as shown in Figure 5.2. IC50 values of these inhibitors for both WT and 
MDR769 HIV-1 protease were measured to determine the binding affinity.  
5.1.4 Lopinaivr 
Lopinavir, approved by FDA in 2000, is the only protease inhibitor that is 
co-formulated with a low dose of ritonavir -- the combination is known as 
Kaletra (Abbott).  In vitro assay showed IC50 of 6-17 nM range against 
various stains (245). Although drug resistance is relatively less likely to 
develop for lopinavir compared to other HIV-1 protease inhibitors (248), 
resistance mutations are noticed, including 32I, 47A, and 46I, or L33F, I54V, 
V82A, I84V, and L90M, or combinations among L76V, M46I, and V82A in the 
protease, or A431V in gag (249-253). In addition, it was found that the 
accumulation of mutations, including mutations of codons 82, 54, and 46, 
during prior protease inhibitor treatment facilitates the emerging of lopinavir 
resistant mutations (254). 
We expect to have worse IC50 values of MDR769 HIV-1 protease against 
both reduced CA/p2 analog library and the FDA approved inhibitors compared 
to those of wild type HIV-1 protease. Based on this working hypothesis, it is 
proposed that reduced CA/p2 analog library and the FDA approved inhibitors 
bind to MDR769 HIV-1 protease with reduced affinity. In addition, the analysis 
of the reduced CA/p2 analog library sequence and FDA approved inhibitor 
structure, combined with the IC50 data, may lead to some hints in how to 
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modify currently existing FDA approved HIV-1 protease to overcome the drug 
resistance issue. 
Table 5.1  CA/p2 reduced peptide librarya. 
Reduced Peptide P3  P2  P1   P1'  P2'  P3'  P4'  
Original CA/p2  Arg  Val  Leu   Ala  Glu  Ala  Met  
P1'F  Arg  Val  Leu  R  Phe  Glu  Ala  NorLeu  
P2A  Arg  Ala  Leu  R  Phe  Glu  Ala  NorLeu  
P2F  Arg  Phe  Leu  R  Phe  Glu  Ala  NorLeu  
P1A  Arg  Val  Ala  R  Phe  Glu  Ala  NorLeu  
P1F  Arg  Val  Phe  R  Phe  Glu  Ala  NorLeu  
P2'A  Arg  Val  Leu  R  Phe  Ala  Ala  NorLeu  
P2'F  Arg  Val  Leu  R  Phe  Phe  Ala  NorLeu  
SP1  Arg  Val  Leu       
SP2      Phe  Glu  Ala  NorLeu  
aThe Sequnces of these peptides are listed from P3 site to P4’ site. The cleavage site 
is between P1 and P1’. The first sequence represents the natural CA/p2 sequence 
with a regular peptide bond between P1 and P1’. The capitalized letter “R” stands for 
reduced peptide bond and makes the peptides uncleavable by active HIV-1 protease. 
The mutagenesis is highlighted by red. The last two peptides SP1 and SP2 stand for 
short peptide 1 and short peptide 2 respectively. They are the N and C terminal 
cleavage products for natural CA/p2 peptide. In addition, the P4’ site is Methionine in 
natural CA/p2 sequence and is mutated to NorLeu to avoid the chemical synthetic 
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obstacles.  
 
 
Fgire 5.1 Comparison of regular and reduced CA/p2 peptide bond. The 
upper panel is the regular CA/p2 peptide and the lower panel is the reduced CA/p2 
peptide. From the left to the right are P3, P2, P1, P1’, P2’, P3’, P4’ site respectively. 
The peptide bond is reduced between P1 and P1’ site in the reduced CA/p2 peptide 
analogs. The P4’ site is mutated from Methionine to NorLeucine to avoid chemical 
synthesis difficulties. P2 to P2’ sites are subjected to mutations in order to explore the 
influences of the binding affinity to HIV-1 protease introduced by different amino acid 
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residues. 
 
 
Figure 5.2 Structure of FDA approved HIV-1 protease inhibitors. The 
structures of six FDA approved inhibitors are shown in this panel. All of these inhibitor 
contain a peptidomimetic hydroxyethylene core. Among these, lopinavir and ritonavir 
demonstrate a symmetric P1/P1’ conformation, while others have different P1/P1’ 
functional groups. 
 
 
 
5.2 Results  
5.2.1 IC50 enzyme data with the reduced CA/p2 peptide analogs 
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The IC50 values for the reduced CA/p2 peptide library are shown in Table 
5.2.  Similar IC50 values are observed between MDR769 and WT HIV-1 
protease against the library of reduced CA/p2 peptide analogs. In addition, the 
SP1 (short peptide 1) and SP2 (short peptide 2), the cleavage products of 
CA/p2, both fail to show feedback inhibition against either MDR HIV-1 
protease or WT HIV-1 protease.  
However, the reduced peptide P1’F with P1’ site Ala replaced by Phe 
shows IC50 4.3 nM against MDR 769 HIV-1 protease, despite being slightly 
higher than that of WT HIV-1 protease. This IC50 is even comparable to IC50 
of some FDA approved HIV-1 protease inhibitors. P1’F with P1 Leu and P1’ 
Phe is a good combination, and we will explore other similar combinations 
based on this.  
 
Table 5.2  IC50 values of CA/p2 reduced peptide library against both 
MDR and WT HIV-1 protease 
Peptide WT IC50 (nM) MDR769 IC 50(nM) 
P1'F  2.6 4.3 ± 0.02 
P2A  78.17  74.1 ± 10.49 
P1F  30.67  142 ± 4 
P2'A  232.33  233.67 ± 3.21 
P2F  1143.33  770.33 ± 62.96 
P2'F  1009.67  1263.33 ±106.93 
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P1A  4873.33  5020 ± 434.86 
SP 1  100000  103866.7 ± 7145.16 
SP 2  N/A 664333.3± 72885.5 
 
5.2.2 IC 50 enzyme data with the six FDA approved HIV-1 protease 
inhibitors 
The IC50 values of six FDA approved protease inhibitors, amprenavir, 
indinavir, lopinaivr, ritonavir, nelfinavir, and saquinavir, against both MDR 769 
and WT HIV-1 protease are given in Table 5.3. Analysis of the data shows 
significant drug resistance of MDR HIV-1 protease against all protease 
inhibitors except for lopinavir, compared to those of WT HIV-1 protease. The 
IC50 increase of lopinavir is only 4-folds from WT to MDR HIV-1 protease. As 
a result, lopinavir is a good starting point to modify the existing FDA approved 
HIV-1 protease inhibitors in order to restore the inhibitor binding affinity without 
dramatically altering the ADME (absorption, distribution, metabolism, and 
elimination) and toxicity of the potential drug candidates. 
 
 
Table 5.3  IC50 values of FDA approved inhibitors against both MDR and 
WT HIV-1 protease 
Inhibitor  WT (nM)   MDR769 (nM)  IC50 increase  
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Amprenavir  0.4763 ±0.031 5.94 ±0.145 12.47  
Indinavir  2.67 ±0.832 142.3 ±23.46 53.29  
Lopinavir  1.237 ±0.139 5.39 ±0.225 4.357  
Ritonavir  0.443 ±0.007 56.17 ±5.34 126.79  
Nelfinavir  2.18 ±0.1 104 ±1.732 47.71  
Saquinavir  0.514 ±0.00436 311.3 ±15.822 605.64  
5.3 Discussion 
5.3.1 Substrate cleaveage efficiency of WT and MDR HIV-1 
proteases 
The chemical cleavage step is disrupted by the mutations in MDR769 
HIV-1 protease. Two independent steps are required for the process of HIV-1 
protease substrates. The first step is the physical binding of the substrates to 
the HIV-1 protease. The second step is the chemical cleavage of the 
substrates, which is executed by the residues Asp 25 and Asp125. Our 
enzyme assay shows similar IC50 values of MDR769 and WT HIV-1 protease 
against the library of reduced CA/p2 peptide analogs. It indicates that the 
binding affinity of this library is similar regardless of the MDR or WT HIV-1 
protease. Meanwhile, other studies indicate certain degree loss of catalytic 
acitivity of MDR HIV-1 protease, compared to that of WT HIV-1 protease, in 
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cleaving the substrate peptides. As a result, it is expected that the chemical 
cleavage step rather than the physical binding step of the substrate peptide is 
disrupted by the drug resistance rendering mutations. This chemical cleavage 
disruption may result from the expanded active site cavity of the MDR HIV-1 
protease. Due to the extra space in the active site cavity allowing relatively free 
movement of the substrate peptides, the substrate peptides are thought to be 
floating in the active site cavity. This makes the substrate peptide cleavage site 
less accessible to the two “active residues” Asp 25 and Asp 125.  
5.3.2 CA/p2 P1’F reduced peptide shows highest IC50 against both 
WT and MDR HIV-1 protease 
It was surprising to learn that the reduced peptide P1’F inhibits the WT and 
MDR HIV-1 protease with IC50 values comparable to those of the FDA 
approved HIV-1 protease inhibitors. Despite the fact that MDR HIV-1 protease 
was slightly resistant to reduced peptide P1’F, the absolute value of the IC50 
indicated that reduced peptide P1’F is a potential drug candidate with P1/P1’ 
combination Leu and Phe. Other similar combinations of P1 and P1’ sites are 
explored to optimize the inhibitory activity of the reduced CA/p2 peptide 
analog. In addition, to further comfirm the importance of the P1/P1’ 
combination, a shorter peptide library, ranging from P2 to P2’ sites rather than 
P3 to P4’, will be synthesized and tested against WT and MDR HIV-1 
protease. 
5.3.3 P1/P1’ site symmetry of lopinaivr may contribute to the 
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enhanced drug efficacy 
Lopinavir shows a four-fold drug resistance by MDR HIV-1 protease. 
Further analysis of lopinavir and other protease inhibitors reveals a unique 
characteristic of lopinavir -- the symmetric P1 and P1’ sites. Ritonavir, similar 
to lopinavir, shows a symmetric P1/P1’ sites, but does not demonstrate similar 
pattern of drug resistance. However, it is possible that the bulky volume of 
ritonavir makes it less potent against MDR HIV-1 protease. The symmetry of 
P1 and P1’ site of lopinavir is under further investigation to understand the 
potential application of the symmetric sidechain concept to HIV-1 protease 
structure based drug design, given the symmetric nature of the enzyme. In 
addition, lopinavir and ritonavir will be cocrystallized with MDR HIV-1 protease 
to understand in details the mechanism of different patterns of drug resistance. 
5.3.4 Implication of the discrepancy between the library of reduced 
CA/p2 peptide analogs and inhibitor IC50 values 
The IC50 values of the library of reduced CA/p2 peptide analogs 
surprisingly fail to show the different binding affinity of the WT and MDR HIV-1 
protease to the substrates. However, the inhibitor enzymatic studies give the 
expected different binding affinities of these inhibitors to WT and MDR HIV-1 
protease, although the difference varies in different inhibitors. The comparison 
between the reduced CA/p2 analogs and FDA approved HIV-1 protease 
inhibitors reveals the following differences: 
1. The reduced CA/p2 peptides comprise of seven amino acid residues, 
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while the inhibitor range from P2 to P’ sites only, equal to four 
amino acid residues in length 
2.  There is one hydroxyl group between the P1 and P1’ sites of the 
protease inhibitor mimicking the crystallographic water critical in 
substrate cleavage in the HIV-1 prtease substrate complex, while 
no such corresponding functional group is observed in the reduced 
CA/p2 peptide analogs 
3. The difference in the environment of the hydroxyethylene carbon  
atom may make a difference in binding affinity. The inhibitors have 
an R1-CH2-CH(OH)-CH2-R2 structure whereas the reduced 
CA/p2 analogs have an R1-CH2-CH2-NH-R2. 
Consequently, there are three possible ways to modify the FDA approved 
inhibitors to overcome the drug resistance issue by restoring the binding 
affinity to MDR HIV-1 protease. First, expand the existing protease inhibitors. 
The extent to which the expansion can reach needs to be carefully calibered. 
On one hand, if the volume is not big enough, the binding affinity is not 
increased enough to achieve the desirable results. One the other hand, an 
over-expanded inhibitor may lose its target specificity and lead to intolerable 
toxicity despite the high activity. In addition, the bioavlaibity may be 
unfavorable with large inhibitors. Second, the hydroxyl group between P1 and 
P1’ sites may be removed or substituted by other functional groups to generate 
the modified inhibitors with better IC50 values and higher binding affinity to the 
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MDR HIV-1 protease. Third, one of the carbon atoms flanking the hydroxyl 
group between P1 and P1’ site may be substituted by a nitrogen atom. Which 
carbon atom to be replaced cannot be determined based on current functional 
studies. Further experiment with either of these two carbons replaced by 
nitrogen atom separately will be helpful in determining the significance of each 
flanking carbon atoms to the ligand binding affinity to the MDR HIV-1 protease. 
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CHAPTER 6: CRYSTAL STRUCTURE OF THE EXTRA-CELLULAR 
DOMAIN OF HUMAN MYELIN PROTEIN ZERO 
6.1 Introduction 
6.1.1 Function of the myelin protein zero  
Myelin protein zero (MPZ) is the causative gene for CMT1B, although it 
is much less common than CMT1A, accounting for less than five percent of all 
CMT1 cases (142,151-152).  
Myelin protein zero (MPZ), associated with CMT1B, is a 
transmembrane protein of 219 amino acid residues. Human MPZ consists of 
three domains: first, 125 residues constitute the glycosylated 
immunoglobulin-like extracellular domain; second, 27 residues span the 
membrane; and third, 67 residues represent the highly basic intracellular 
domain (160-161). MPZ, a homophilic adhesion molecule (162-164), is a 
member of the immunoglobulin super-family (165) and is essential for normal 
myelin structure and function. 
6.1.2 Structure of the extracellular domain of human MPZ 
We report the crystal structure of the extracellular domain of human MPZ 
(hP0ex) fused with the maltose binding protein (MBP) at resolution 2.1 Å. 
Despite the fact that the crystal structure of rat MPZ extracellular domain 
(rP0ex) is available (166), the crystal structure of the human counterpart is 
indispensible considering several critical amino acid residue variations 
between the two homologues . There are three sequence differences at amino 
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acid residues 10, 16 and 77. Residue 10 is a clinically important site where a 
mutation may lead to phenotypic change. MPZ residues 16 and 77 are at the 
four-fold interface and head-to-head interface according to the packing of the 
rat P0ex model. Consequently, the crystal structure of the human P0ex is 
necessary to understand the mechanism of CMT disease. 
6.1.3 Functional studies of clinically important mutants of MPZ 
In addition, based on the crystal structure of hP0ex, we investigate the 
molecular mechanism of pathogenesis of MPZ mutants H10P, R69C, R69H, 
T95M, and H52R. First, Li et al demonstrated that mutant H10P, causes late 
onset CMT1B and presents severe length-dependent axonal loss without 
segmental demyelination.  Material either in the inner wraps of myelin and/or 
periaxonal space coexisted with the accumulated MPZ. In addition, the 
molecular organization of the axolemma (Mauthner sheath or plasma 
membrane of the axon) showed abnormalities (255). Second, R69C mutations 
caused an early onset CMT1B (256-258). Further investigation showed 
regions of uncompacted myelin, one of the two types of pathology as seen in 
other early onset CMT1B (259-260). Onion bulb formation, thinly myelinated 
axons (261), and amyelinated fibers were also noticed in this mutant. Third, 
T95M, a mutation leading to later onset CMT1B, did not interrupt the normal 
intracellular traffic of MPZ and affected the intercellular adhesion moderately. 
However, this mutation interfered with the glycosylation of MPZ, which is 
important for MPZ function. Fourth, mutation H52R, unlike other early onset 
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CMT1B causing mutations, showed no adverse affects on the intracellular 
traffic of MPZ. The MPZ with mutation H52R could reach the cell surface but it 
significantly reduced the intercellular adhesion (262).  
6.1.4 Amyloidosis and CMT1B 
Recent studies have linked amyloidosis to CMT1B caused by certain 
mutations such as T95M (263). In amyloidosis, amyloid fibrils, derived from 
naturally soluble protein or protein fragments, are insoluble and accumulate in 
a variety of organs and tissues (264-267). The orginal naturally soluble 
proteins are unrelated and may be rich in β sheet, α helix, or both α helices 
and β sheets. They may be rigid globular proteins or natively unfolded proteins 
(268-274). However, the amyloid fibrils contain a common core structure of 
cross folded β-sheets, consisting of continous β sheets with the β strands 
running perpendicular to the long axis of the fibrils (275). Immunoglobulin light 
chain amyloidosis (AL amyloidosis), associated with a plasma-cell dysfunction 
(276), is the most common amyloidosis in the US (277).The immuolglobulin 
light chains, light chains and heavy chains, or fragments of heavy chains 
cannot be broken down to constituent amino acids due to the misfolding (278). 
The light chains assemble into protofibril and then into amyloid fibril in the form 
of an amyloid fribril subunit (279). The light chain of immunoglobulin contains 
two immulogolulin fold structures, while the extra cellular domain of human 
MPZ has a single immunoglobulin fold structure. It is possible that the X-ray 
diffraction studies will reveal an amyloid structure of the hP0ex mutants that 
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causes CMT1B. Further studies of the β-pleated sheet binding to Congo red 
with its tinctorial properties of green birefringence under polarized light may 
provide an alternative way to study the hP0ex mutants besides the the unique 
X-ray diffraction pattern. Amyloid protein diffraction patterns show 
characteristic perpendicular reflections along the meridional direcction at 4.7 Å 
and along the equatorial direction at 10 Å (280). 
6.2 RESULTS  
6.2.1 Crystal structure of the MBP hP0ex fusion 
hP0ex fused with MBP crystallized in space group P21. The 
crystallographic parameters are shown in Table 6.1 with the final structure 
refined to 2.1 Å resolution. The electron density maps, contoured at 2 sigma, of 
the maltose in the MBP and the intra-molecular disulfide bond in the hP0ex are 
shown in Figure 6.2. Two fusion proteins are included in one crystallographic 
asymmetric unit, with one maltose ligand in each MBP molecule (Fig. 6.1). The 
MBP adopts the “closed” conformation in the presence of the maltose 
molecule. The connecting region (22 amino acid residues, part of the 
pMal™-p2X vector) between the C-terminus of MBP and the N-terminus of 
hP0ex was difficult to trace and therefore was omitted due to the poor electron 
density of these residues. As a result, one fusion protein molecule was treated 
as two independent chains in the deposited PDB file. Two intact hP0ex (from 
residue 1 to residue 121) were present in one crystallographic asymmetric unit. 
The last four residues of the C-terminus, 122 - 125 (Pro, Thr, Arg, and Tyr), 
115 
 
 
were disordered due to flexibility and therefore omitted. The major interface in 
the crystal was between two MBP interfaces involving residues Asp 120 (Asn 
205, Lys 202 of molecule two), Lys 239 (Asn201 of molecule two), Asp 314 
(Lys 142 of molecule two), Pro 315 (Gly 143 of molecule two), and Arg 316 
(Ala141 of molecule two). hP0ex Arg 77 only contacted MBP via Glu 359 
because of the flexible connecting region; hence, no significant obstruction of 
the quaternary structure was induced by the close proximity of the large MBP 
domain.   
 
Table 6.1 Data Collection and Crystallographic Refinement Statistics 
Data Collection  
Beam Line  APS (LS-CAT 21) 
Wavelength (Å)   0.9779 
Space group   P2(1) 
Cell dimension (Å) a, b, c a=61.91 b=54.77 
c=145.85 
α, β, γ α=90.00 β=98.49 
γ=90.00 
Resolution (Å) 30.00-2.00 
R merge (%)a 8.7/53.9b 
I/σ(I)   21.6/4.3 
Redundancy 3.5/3.4 
Completeness (%) 99.9/100 
Unique reflectionc 77053 
Refinement  
Resolution range (Å) 19.96-2.1 
R work (%)d 19.2 
R free (%)e 25.9 
No. of protein residue 976 
No. of water molecule 507 
B factor   
Whole molecules 28.995 
Side chain (include water) 30.311 
Main chain   27.543 
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Ligand (Maltose E/F)   18.109/17.607 
Solvent 36.411 
RMSD  
Bond length 0.012 
Bond angle  1.597 
Ramachandran Plot  
Favorable (%)                                                  89.3 
Additional (%) 9.1 
Generous (%) 1.7 
Forbidden (%)   0 
PDB accession ID 3OAI 
aRmerge= ΣhklΣi|I(hkl)i-{I(hkl)|/ ΣhklΣiI(hkl)i , where I(hkl)i is the intensity of an 
observation and I(hkl) is the mean value for its unique reflection. Summations cover 
all reflections. 
bThe values after the hyphens indicate the highest resolution shell. 
cNobs/Nunique. 
dRwork= Σhkl|F(hkl)o- {F(hk|/ΣhklF(hkl)o 
eR free was calculated same way as R working, but with the reflections excluded from 
refinement. The R free set was chosen using default parameters in Refmac 5 
6.2.2 Crystal Structure of hP0ex  
It was predicted and found that hP0ex domain shows significant similarity to 
the members of the immunoglobulin family (281), specifically, a v-type 
immunoglobulin fold (282). The structure of rP0ex, a homolog of hP0ex, has  
also been assigned to the immunoglobulin superfamily (166). Our crystal 
structure further confirmed this finding (Figure 6.1 and Figure 6.3). The 
structure consists of nine antiparallel β strands forming a barrel-like shape. 
However, as with other immunoglobulin superfamily members, the hydrogen 
bonds do not go around the barrel, the structure is physically a β-sandwich 
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comprised of two distinct β-plated sheets (283). Strands D, E, B, and A make 
up one β sheet, while strands D, F, C, C’, C’’ constitute the other β sheet. In 
spite of the proximity between strands A and B, the entire length of strand A 
forms hydrogen bonds with strand G. A similar conformation is seen in 
molecules CD2 (284) and CD4 with a truncated strand A (285-286). In some 
other immunoglobulin superfamily members such as CD8 (287) and VCAM-1 
(288), the first half of the strand A forms hydrogen bonds with the strand B, 
while the second half forms hydrogen bonds to strand G. Strands B, C, E, F, 
and G present a rigid hydrophobic core characteristic of immunoglobulin 
variable domains. In addition, one conserved disulfide bond is also found 
bridging strands B and F.  
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Figure 6.1. Crystal structure of the fusion protein MBP- hP0ex. In green 
color is the closed-form of MBP with a maltose molecule. In blue color is the hP0ex 
and the linker connecting MBP and hP0ex is presented by dotted line due to 
disordered structure. 
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Figure 6.2 The electron density map of maltose and disulfide bond at 2.0 
sigma. Upper panel shows the MBP with maltose molecule. The lower panel shows 
the intra-molecular disulfide bond in hP0ex. The electron density map is rendered by 
a blue mesh.   
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6.2.3 The overall structures of hP0ex and rP0ex are similar 
Although three residues differ between hP0ex and rP0ex (H10Y, R16Q, 
and R77S), the overall structures of hP0ex and rP0ex are quite similar (Figure 
6.4). These mutations are located on the surface of the hP0ex, making hP0ex 
more basic compared to rP0ex. The overall more basic characteristic of hP0ex 
may be important in understanding the differences between human and rat 
Schwann cell functions. The two crystal structures also differ at the FG loop 
which is continuous in hP0ex but broken in rP0ex due to four disordered 
residues (Pro103, Pro104, Asp105, and Ile106, Figure 6.4).  
Secondary structure analysis based on the hP0ex and rP0ex structures 
rendered with the program PyMOL, revealed almost identical secondary 
structure compositions. Both hP0ex and rP0ex represent a typical v-type 
immunoglobulin fold (282). The difference between the two structures is that 
some β strands in the hP0ex are missing. The loss of some secondary 
structure elements in hP0ex makes it relatively more flexible. For instance, 
strands A’ and B’ are not seen and helix 1 (residues 76 to 78) is missing in 
hP0ex . The absence of helix 1 in hP0ex may be partially due to the change of  
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Figure 6.3.  hP0ex forms a v-type immunoglobulin fold. The secondary 
structure elements are highlighted by different colors. β strands are shown in blue and 
the helices are in brown color and loops are in black. The intra-molecular disulfide 
bond is shown in dark yellow.  
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Figure 6.4.  Comparison between hP0ex (blue) and rP0ex (purple and 
black dots). The overall structures are highly conserved between the two species, 
considering the similarity in the amino acid sequence. However, the hP0ex structure 
contains the amino acid sequences that are difficult to track due to the broken electron 
density map for rP0ex.  
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codon 77 from Arg in hP0ex to Ser in rP0ex. The other two variations between 
hP0ex and rP0ex, H10Y and R16Q, appear not to alter the secondary 
structure 
6.2.4 Some regions in hP0ex show high flexibility relative to rP0ex 
Superposition based on Cα of the hP0ex and rP0ex structure shows 
high root mean square deviations (RMSD) in some regions. RMSD is more 
than 1 Å for both main chain and side chain in the following regions: the 
N-terminus (residues 1 and 2), loop BC (residues from 25 to 32), loop C’’D 
(residues 62, 63 and 64), both ends of the disordered loop in rP0ex (residues 
102 and 107). RSMD analysis shows abnormally high RMSD regions (side 
chain only) in the following: N-terminus (residue 4), Strand A ( residues 7, 8 
and 10), loop AB ( residue14), loop BC ( residues 23,24, and 33), loop CC’ 
( residues 45 and 46), strand C’ (residues 48 and 49), loop C’C’’ (residues 54 
and 55), strand C’’ (residues57, 58 and 60), loop C’’D (residues 61, 65, 67 and 
70), loop DE (residues 78, 79 and 83), the broken ends in rP0ex (residues 101 
and 109), strand G ( residue112), and C-terminus (residue119). Areas 
surrounding the three variation sites show high RMSD values (Figure 6.5). 
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Figure 6.5 The RMSD digram based on the superposition of hP0ex and 
rP0ex on the Cα. The X axis is the residue number and the Y axis the RMSD value. 
The series 1 (blue) represents the main chain RMSD and the series 2 (purple) is the 
RMSD of the side chain. The corresponding missing residues in hP0ex from residues 
103 to 106 are omitted in the comparison. In addition, to facilitate the comparison, 
residues after 102 are renumbered.  
 
6.2.5 The ß-strand A in hP0ex is relatively shorter than the matching 
ß-strand in rP0ex 
Although the core of the immunoglobulin fold between hP0ex and rP0ex, 
consisting of strands B, C, E, F, and G, is highly conserved, the most significant 
difference among β strands is located in strand A. In hP0ex, strand A is 
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relatively shorter than that in rP0ex, forming hydrogen bonds only with strand 
G. In contrast, strand A in rP0ex is divided into two small strands, A and A’. In 
rP0ex, strand A forms hydrogen bonds with the strand B, and strand A’ forms 
hydrogen bonds with strand G (Figure 6.4), as seen in CD8 (287) and VCAM-1 
(288). As a result, the stand A in hP0ex is relatively flexible compared with that 
in rP0ex. Subsequent mutations on strand A, such as H10P, may further 
destabilize strand A in hP0ex. 
6.2.6 Surface area of hP0ex is larger than the surface area of rP0ex 
The surface area in hP0ex (with 552 surface atoms from 115 residues) 
is increased by 155.9 Å2 compared to that of rP0ex (with 561 surface atoms 
from 115 residues). The individual amino acid residue surface areas are shown 
in Figures 6.6 and 6.7. The surface areas of residues 1, 2, 7, 8, 16, 24, 32, 57, 
65, 77, 101, and 119 are increased each by at least 20 Å2, while surface areas 
of residues 10, 62, 64, 97, 102, and 107 are each decreased by more than 20 
Å2. The surface area changes at residues 10, 16, and 77 are due to the 
sequence variation between the human and rat protein. The surface area 
changes at residues 1, 2, 101, 102, 107, and 119 may be caused by the 
flexibility of N- and C- termini and the broken ends within rP0ex. The increased 
extracellular surface area of hP0ex may strengthen the interactions among 
hP0ex molecules on the surface of Schwann cells, leading to higher affinity 
between homophilic molecules. 
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Figure 6.6 The surface area of individual amino acid residues in both 
hP0ex and rP0ex. The X axis is the amino acid residue number and the Y axis is 
the surface area of individual amino acid residues in square Angstroms. The blue 
series represents the surface area of hP0ex residues and the purple series represents 
the surface area of rP0ex amino acid residues. The overall surface area distribution is 
similar between hP0ex and rP0ex, however certain amino acid residues show large 
surface area differences that may affect the overall stability of the molecules and 
inter-molecule interactions. The corresponding missing residues in hP0ex from 
residues 103 to 106 are omitted in the comparison. In addition, to facilitate the 
comparison, residues after 102 are renumbered. 
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Figure 6.7. The difference of surface area of individual amino acid 
residues between hP0ex and rP0ex. The X axis is the amino acid residue 
number and the Y axis is the surface area difference of individual amino acid residues. 
The overall surface area distribution is simlar between hP0ex and rP0ex, however, 
certain amino acid residues show large surface area differences that may affect the 
overall stability of the molecules and inter-molecule interactions. The corresponding 
missing residues in hP0ex from residues 103 to 106 are omitted in the comparison. In 
addition, to facilitate the comparison, residues after 102 are renumbered. 
 
 
 
 
6.3 Discussion  
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6.3.1 hP0ex tetramer assembly based on the rP0ex tetramer 
An hP0ex tetramer was assembled to investigate the hP0ex homophilic 
adhesion capacity based on the rP0ex tetramer conformation. Although the 
hP0ex tetramer does not exist in the crystals, due to steric hindrance from the 
MBP chain, the hP0ex tetramer is plausible both from the aspect of proposed 
hP0ex homophilic adhesion capacity and from the crystal structure of rP0ex 
showing a tetramer conformation.  
 The rP0ex tetramer is generated through symmetry operations based on 
the rat tetramer model (166). Four individual hP0ex molecules are superposed 
onto the rP0ex tetramer. The four resultant hP0ex molecules from the 
superposition are combined to give a hypothetical hP0ex tetramer (Figure 6.8). 
The hP0ex and rP0ex tetramers are highly conserved, which is essentially 
determined by the similarity between hP0ex and rP0ex monomer molecules. 
However, there are three key differences between the human and rat 
tetramer model. First, in the hP0ex tetramers, the interaction between loop BC 
of one molecule and loop C’’D and EF of the next molecule in the four-fold 
interface as defined by Shapiro et al.(166) is stronger than in the rP0ex 
tetramers. In the rP0ex tetramer, a stacking interaction is formed between Trp 
24 in loop BC (of one monomer) and His 86 in loop EF (of the adjacent rP0ex 
monomer) due to the relatively long distance. However, in the modeled hP0ex 
tetramer the side chains of Trp 24 in loop BC (of one monomer) and His 86 in 
loop EF (of the adjacent monomer) are too close to one another and they 
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appear to clash. Second, the N-terminus of hP0ex is more flexible and forms a 
loop, while the N-terminus of rP0ex is more organized in the form of a β strand. 
As a result, the hP0ex N-terminus of one molecule is bent toward the loop EF 
of the next hP0ex, forming two extra hydrogen bonds between Ile 1 and Asn 87. 
In contrast, the N-terminus of rP0ex forms hydrogen bonds with strand B within 
the same molecule. Third, the C-termini of hP0ex are thought to form anchors 
by which the hP0ex tetramers are attached to the Schwann cell membrane. It 
is anticipated that the C-termini point away from the tetramer structure and 
toward the membrane. However, the structure we solved does not support the 
above model. The four C-termini from the four monomers curve back into the 
donut-like hole within the tetramer. This curving of the C-terminus may be 
explained by the lack of membrane interaction and molecular flexibility.  
6.3.2 Five clinically important mutations of hP0ex  
Five clinically important mutations on hP0ex are under investigation, 
specifically, H10P, R69C, R69H, T95M, and H52R. These mutations are 
dispersed throughout the entire hP0ex molecule, as shown in Figure 6.9. 
Mutation H10P is located on strand A and mutations R69C and R69H are 
located on loop C’’D. Mutation T95M is on strand F and mutation H52R is on 
stand C’. All these mutations lead to early or late onset neuro-degenerative 
disease. 
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Figure 6.8. Superposition of hP0ex tetramer (blue) and rP0ex tetramer 
(purple). A tetramer does not exist in the hP0ex crystal structure. However, a 
tetramer has been identified as the “biological structure” in the rP0ex cystal. The same 
crystallographic symmetry operation is performed to generate the tetramer structure 
of hP0ex. The two tetramer structures of hP0ex and rP0ex then are superposed 
based on the Cα atoms. As shown in this figure, the two tetramer structures overlay 
each other well. However, further investigation reveals that some steric conflicts exist 
among the hP0ex monomers on the inter-molecule surface.  
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Figure 6.9 hP0ex monomer with H10P, R69C, T95M, and H52R mutations. 
The clinically important mutations are shown by a stick model. The intra-disulfide 
bond is shown in dark yellow color. 
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The five clinically important mutations are highlighted in the hP0ex 
tetramer to investigate the structural influences imposed by these mutations on 
hP0ex function (Figure. 6.10). While mutation H10P is not on any 
inter-molecular interface within or between the hP0ex tetramers, it might 
disrupt the hP0ex monomer structure. In the H10P mutant, no obvious 
interruption in the tetramer structure is predicted. However, as the modeling 
prediction of the H10P structure indicates, the introduction of mutation H10P 
may disrupt the intra-molecular disulfide bond and thus lead to structural 
instability of the hP0ex monomers (unpublished results). The disruption of the 
hP0ex monomer structure, in turn, may affect the tetramer formation and its 
function. A discussion of the other four clinically important mutations follows in 
the next paragraph. 
Mutations R69C and R69H may reduce the homophilic adhesion 
capacity of hP0ex through disruption or weakening of hP0ex tetramers. These 
mutations are located on loop C’’D, which is an important inter-molecular 
interface for tethering four hP0ex monomers together in the hP0ex tetramer. 
The mutation from Arg to either Cys or His shortens the side chain of the 
residue 69 and may result in weakened interaction between the loop C’’D from 
one monomer and the loop BC from the adjacent monomer. Mutations T95M 
and H52R are on the outer surface of the hP0ex tetramer and might influence 
the hP0ex function by disrupting inter-tetramer interactions.  
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Figure 6.10. Important mutations shown in the hP0ex tetramer. The ribbons 
in different color are individual hP0ex monomers. Mutations are shown by stick model. 
The anaylsis of the structural influences introduced by the mutations is limited if the 
analysis is confined to the hP0ex monomers. Visualization of the mutations in the 
hP0ex tetramer takes into account the possible intra-monomer, inter-monomer, and 
inter-tertramer structural disruptions induced by these mutations, thus more 
comprehensive in the analysis.  
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6.3.3 Prediction of the structure of H10P hP0ex 
The histidine residue at position 10 of the human MPZ coding sequence 
is one of three amino acids that differ between the human and rat MPZ 
extracellular domains, and is one of 8 amino acids located within a ß-strand in 
which the root mean square deviation between the human and rat proteins is 
greater than 1 Å. Mutation of this residue to proline (H10P) causes a late onset 
form of CMT1B in several large families (155). Nerve conduction velocities in 
affected individuals are preserved, suggesting that myelin can functional 
normally. The peripheral nerve pathology associated with the H10P mutation, 
however, demonstrates accumulation of proteinaceous material between 
Schwann cells and axons, as well as focal areas of tomaculous-like myelin 
disruption (functional disturbance or pathological change), suggesting 
abnormal myelin breakdown and/or turnover.  
In order to investigate a structural contribution to the H10P phenotype, 
we have used the crystal structure of the hMPZex to predict the hMPZex H10P 
structure by performing molecular modeling. The result of the simulation 
demonstrates several important changes in the MPZ structure caused by the 
H10P mutation. Because of the proline at residue 10, the N-terminus now 
forms an A’ ß-strand similar to that in the rat MPZ which gives rise to an 
anti-parallel ß-sheet with the downstream segment of the B strand pulling the 
A’ strand toward the N-terminus and away from the F strand. As a 
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consequence, the distance between Cys21 and Cys98, located on the B and F 
strands, is increased to 3.7 Å, thus the disulfide bond between these two 
residues can no longer form. Absence of the disulfide bond between the two 
ß-sheets, a highly conserved element of Ig domain structure, probably causes 
the H10P mutant to be less stable than its wild type counterpart. In addition, 
the two cysteine residues could interact with free cysteines from other proteins, 
leading to the formation of disulfide-linked MPZ complexes. The substitution of 
proline at position 10 also directly alters the protein backbone by producing a 
“kink” at that location. A comparison of the wild type and H10P mutant forms of 
hMPZex is shown in Figure 6.11.  
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Figure 6.11. Structural comparison of the wild type and H10P mutant 
forms of MPZex. The left panel shows the superposition of the wild type (sky blue) 
and predicted H10P-MPZex (gold). The right panel more closely focuses on the 
disulfide bond region, showing the broken disulfide bond in H10P-MPZex. The overall 
structure of wild type MPZex and the H10P-MPZex are similar. However, the broken 
disulfur bond indicates the possibility of inter-meluclar disulfur bonds, which may be 
the reason of oligomerization of the H10P-MPZex.  
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6.3.4 Crystallization of proteins fused to the maltose binding 
protein 
According to a recent report from the Joint Center for Structural Genomics 
(http://www.jcsg.org), among all the proteins that are expressed, only 9.8% 
could be crystallized with favorable size and quality for X-ray screening. 74% 
of these crystals diffract X-ray for further data collection. Furthermore, only 
50% of these crystals with diffraction data can be solved. As a result, the most 
serious obstacle for crystallographers is to grow high quality protein crystals. 
Several different methods were developed recently to facilitate the 
crystallization of proteins that were previous refractory to crystallization (289). 
These methods include optimization of target constructs, noncovalent 
crystallization chaperones, removal of post-translational modifications, 
stabilization of protein targets, surface-entropy reduction (SER), improvement 
of crystal quality, and the use of fusion proteins for crystallization.  
Different carrier fusion proteins have be used, a tag protein fused with the 
target protein, to facilitate protein crystallization, such as maltose binding 
protein (MBP), thioredoxin (TRX) (290-291), glutathione-S-transferase (GST) 
(292-295) and lysozyme (296-299). Usually the presence of the tag proteion 
helps increasing both the expression and solubility of the target protein 
(300-302), in addition to the simplification of protocol of target protein 
purification if the tag proteins are affinity tags (303-304).  
Among all the potential tag proteins, the protein with highest success rate 
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is the maltose binding protein. It is usually added on the N-terminus of the 
target protein and can act as a chaperone-like protein to facilitate the proper 
folding of the targets (305-306). The protein crystals obtained through the 
fusion of MBP are listed in Table 6.2.  
However, it is not uncommon that the target proteins are still refractory to 
crystallization despite of the presence of MBP to increase the expression and 
solubility (307-310). In these cases, we may introduce some mutations on 
MBP itself in order to achieve the goal of maximal surface entropy reductions 
(SER) (311-313). 
However, the addition of the MBP tag to the target proteins may itself 
cause some undesirable outcomes. The MBP itself is more than 300 amino 
acid residues, thus limit the size of target proteins that are suitable for E. coli 
expression system. The presence of MBP on the N-terminus of the target 
protein may disrupt the native structure of the target protein, especially when 
the N-terminus of the target protein is functionally important and is involved in 
certain structural interactions. In addition, the linker region connecting the MBP 
and the target proteins may introduce significant structural heterogeneity, 
compromising the quality of the crystals. To partially solve this problem, the 
most effective method is to minimize the length of the linker region.  
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Table 6.2. Crystal structures with maltose binding protein as the large 
affinity tags.  Addapted from Moon et. al.(314) 
Target protein Size (AA) Resolution 
(A ° )  
Linker sequence 
HBS antigen(315) 14 2.7-2.9 GS 
IAP(316) 22 1.75-1.86 AAA 
MutS (C-term)(317) 34 2.0 HM 
MATa(187) 50 2.1-2.3 AAAAA 
Huntingtin 
(N-term)(318) 
66 3.5-3.7 AAA 
TIM40/MIA40(319) 82 3.0 SSSVPGRGSIEGRPEF 
gp21(186) 88 2.5 AAA 
Monobody YSX1(320) 91 2.0 GSSGSS 
Monobody YS1(320) 93 1.8 GSS 
IPS1 CARD domain(321) 93 2.1 SAMA 
CRFR1 ECD(322) 96 1.96-3.4 AAAEF 
ZP3 (ZP-N domain)(323) 102 2.3-3.1 AAA 
L30(324) 103 2.31 SSSVPGRGSIEGRA 
gp21(325) 108 - AAA 
designed helical 
protein(326) 
108 1.9 SSSNNNNNNNNNN 
SarR(185) 115 2.3 AAAEF 
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Argonaute2 PAZ (327) 136 2.8 AAAEF 
PTH1R ECD(328) 174 1.95 AAAEF 
CD38(329) 256 2.4 N/Ab 
2OST(330) 298 2.65 AAA 
RACK1A(331) 324 2.4 AAA 
NEDD8(332) 431 2.8 AAA 
hP0exc 121 2.1 AAA 
a
 All target proteins listed in this table are fused C-terminal to the carrier protein, 
unless otherwise stated. 
b
 Information not available. 
c The structure discussed in this dissertation. 
6.3.5 Amyloidosis and CMT1B 
Crystallization attempts, including the in-house and high-throughput 
screens, have been performed to obtain diffration quality crystals of mutants of 
hP0ex, such as H10P and R69H. However, no crystals were obtained despite 
the thorough screening. The fact that mutants are refractory to crystallization 
may indicate that a single mutation introduces a major structural disturbance 
into the fusion protein. The target hP0ex mutants may be disoriented in the 
crystal lattice established by the malose binding protein. Another possibility is 
that the hP0ex mutants form amyloids depite the presence of maltose binding 
protein. If the second hypothesis is correct, the protein sample is expected to 
show characteristic tinctorial properties of green birefringence under polarized 
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light after it is stained with the dye Congo red. Futher experiments might 
include expression and purification of hP0ex mutant without maltose binding 
protein to enhance the possibility of amyloid formation compared to the protein 
fused with maltose binding protein. 
Theoretically, it is possible that amyloid formation is deferred or even 
blocked if a certain small molecule binds to the altered structure of hP0ex 
without introducing any major structural or functional changes, In silico 
screening is currently performed to identify small molecules with high binding 
affinity to the hP0ex mutants. The identified molecules could be evaluated for 
efficacy in a transgenic mouse model with a MPZ knockout. These molecules 
are potential drug candidates to alleviate the signs and symptoms, and/or 
blocking the progression of CMT1B disease. 
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CHAPTER 7: SUMMARY AND FUTURE DIRECTIONS 
7.1 Summary 
7.1.1 Summary of the MDR HIV-1 protease project 
• No significant conformational changes are observed at the point of 
additional mutation in each of the corresponding MDR 769 HIV-1 
protease variants. 
• The proline 81 switch in the MDR769 I10V mutant HIV-1 protease leads 
to signifant conformational changes of the active site cavity. 
• The Phe82 side chain in the MDR769 A82F mutant reveals the 
flipped-out conformation. 
• The hydroxyl group on the side chain of residue 82 points away from the 
active site cavity in A82S while it is pointing towards residues Leu23.  
• The wild type and A82F mutant protease dimers display a larger surface 
area at the dimer interface. 
• Molecular dynamics simulations show two-fold and three-fold opening 
of the flaps in the MDR and wild type HIV-1 proteases. 
• The substrate (Gag-Capsid) is less stable in the expanded active site 
cavity of the MDR769HIV-1 protease. 
• The conformationa of the substrate (Gag-Capsid) is changed during the 
MD simulations. 
• The substrate cleavage site in MDR protease-substrate complex fails to 
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align between the catalytic aspartic acid residues after the MD 
simulations. 
• No significant differences are noticed for the IC50 values of the reduced 
CA/p2 peptide library against MDR and WT HIV-1 protease. 
• Reduced peptide P1’F shows IC50 value against MDR HIV-1 protease 
comparable to that of FDA approved HIV-1 protease inhibitors. 
• All six FDA approved inhibitors (amprenavir, indinavir, lopinaivr, 
ritonavir, nelfinavir and saquinavir) are resisted by MDR HIV-1 
protease. 
• Lopinavir is the least resisted HIV-1 protease inhibitor among the six 
inhibitors. 
7.1.2 Summary of the human myelin protein zero project 
• The overall crystal structures of hP0ex and rP0ex are similar. 
• Certain regions in hP0ex show high flexibility relative to rP0ex. 
• The surface area of hP0ex is larger than the surface area of rP0ex. 
• Molecular dynamics simulation of mutant H10P indicates the interrupted 
intra-molecular disulfide bonds. 
• The presence of the maltose binding protein facilitates the 
crystallization of hP0ex. 
7.2 Future directions 
7.2.1 Future directions of the HIV-1 protease project 
• Measure the Km and kcat of MDR769 HIV-1 protease with nine different 
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natural substrate peptides. 
• Chemically synthesize more potential HIV-1 protease inhibitors to 
overcome the drug resistance issue. 
• Test the inhibitory activity of the synthesized drug candidates against 
both the WT and MDR HIV-1 protease. 
• Perform in silico screening to identify potent drug candidates against 
MDR769 HIV-1 protease. 
• Crystallize other three strains of MDR HIV-1 proteases in the lab. 
• Cocrystallize the nine natural substrate peptides to reveal the substrate 
envelope of the MDR769 HIV-1 protease. 
• Cocrystallize the FDA approved HIV-1 protease inhibitors with the 
MDR769 HIV-1 protease to reveal the structural basis of drug 
resistance against the FDA approved inhibitors. 
•  Based on the crystal structure of the MDR769 HIV-1 protease inhibitor 
complexes, further molecular dynamics simulation is performed to 
reveal the mechanism of drug resistance. 
7.2.2 Future directions of the human myelin protein zero project 
• Perform in silico molecular dynamical simulations of mutants based on 
the extracellular domain of WT human myelin protein zero to reveal the 
molecular mechanism of Charcot-Marie-Tooth disease 1B. 
• Run in silico screening and docking to look for small molecules with 
high binding affinities to the extracellular domain of WT human myelin 
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protein zero. The binding of these small molecules may alter the 
conformation of MPZ and lead to alleviation of the signs and symptoms 
of Charcot-Marie-Tooth disease 1B. 
• Continue crystallization trials of the extracellular domain of the human 
myelin protein zero with mutations at H10P and R69H. 
• Stain the human myelin protein zero with mutations H10P and R69H 
using Congo red to examine the presence of amyloid that shows 
characteristic green birefringence under polarized light. 
• Perform the X-ray scattering diffraction studies on human myelin protein 
zero with mutations H10P and R69H to look for the signagure diffraction 
pattern of amyloid at wavelength 4.7 Å and 10 Å.  
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ABSTRACT 
CRYSTALLOGRAPHIC, MOLECULAR DYNAMICS, AND ENZYMATIC 
STUDIES OF MULTI-DRUG RESISTANT HIV-1 PROTEASE AND 
IMPLICATIONS FOR STRUCTURE BASED DRUG DESIGN (PROJECT 1); 
CRYSTALLOGRAPHIC STUDIES OF HUMAN MYELIN PROTEIN ZERO 
(PROJECT 2) 
by 
ZHIGANG LIU 
May 2011 
Advisor: Dr. Ladislau C. Kovari 
Major: Biochemistry and Molecular Biology 
Degree: Doctor of Philosophy 
PROJECT 1 
Under drug selective pressure, emerging mutations render HIV-1 protease 
drug resistant, leading to antiretroviral therapy failure. The multidrug-resistant 
isolate 769 (MDR769) of HIV-1 protease, with resistance mutations at residues 
10, 36, 46, 54, 62, 63, 71, 82, 84, 90, was selected for the present study to 
investigate the drug resistance issue. 
Ten additional mutations were introduced into to MDR769 HIV-1 protease 
to study the structural influences introduced by these mutations. We obtained 
crystal structures of four variants (I10V, A82F, A82S and A82T) of MDR769 
HIV-1 protease. All these mutations failed to further open the flaps and further 
expand the active site cavity of MDR769 HIV-1 protease, which was 
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characterized by wide open flaps and expanded active site cacity. The 
conserved flaps and active site cavity, despite the introduction of additional 
mutations, indicated that the MDR769 HIV-1 protease represented the end 
stage form of HIV-1 protease. In addition, these crystal structures provided the 
first structure based evidence for the mutation induced conformational 
changes in the 80s loops of the HIV-1 protease apo-enzyme, although the flap 
and active site cavity were not changed dramatically. The alternate 
conformations of Pro81 (proline switch) in the I10V mutant and the side chain 
of Phe82 with flipped-out conformation in A82F mutant showed distorted 
S1/S1’ binding pockets that caused loss of contacts and unstable binding of 
the inhibitors. Similarly, the mutants A82S and A82T showed distortion in the 
S1/S1’ binding pockets due to local changes in the electrostatics caused by the 
mutation from non-polar to polar residues.  
Molecular mechanics studies performed to understand the wide-open 
nature of the MDR769 HIV-1 protease flaps showed that the MDR protease 
exhibited a state of conformational rigidity with respect to the flap closure 
compared to that of the wild type protease. This suggested that the 
accumulation of mutations changed the structure of the MDR HIV-1 protease 
and resulted in a cumulative steric hindrance during the flap closure. Our 
studies showed that modeling a substrate (Gag – Capsid) into the active site 
cavity of the MDR protease did not result in flap closure. Since flap closure 
was crucial in protease inhibitor binding, the conformational rigidity of MDR 
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protease might represent a novel mechanism for multidrug-resistance of the 
MDR protease. In addition, our molecular dynamics simulation revealed the 
realignment of the substrate peptide in the MDR769 HIV-1 protease, making it 
less accessible to the Asp25 and Asp125 amino acid residues in the active site. 
This finding indirectly indicated the reduced catalytic activity of MDR769 HIV-1 
protease in substrate cleavage compared to that of the WT HIV-1 protease.  
The IC50 values of the FDA approved HIV-1 protease inhibitors and the 
library of reduced CA/p2 peptide analogs were measured. The results 
indicated that the reduced peptide analogs bind to the MDR769 HIV-1 
protease and WT HIV-1 protease with equal affinity, while the FDA approved 
inhibitors showed reduced binding affinity to the MDR769 HIV-1 protease 
compared to that of WT HIV-1 protease. The enzyme measurements 
demonstrated that lopinavir was the least resistant HIV-1 protease inhibitor 
and that reduced peptide P1’F was comparable to FDA approved inhibitors 
from the aspect of the inhibitory activity against HIV-1 protease. 
Based on these studies, a library of potential drug candidates against 
HIV-1 protease was proposed to overcome the drug resistance issue. These 
drug candidates are being synthesized in the lab and will be evaluated in the 
future. 
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PROJECT 2 
The wild type extracellular domain of human myelin protein zero (hP0ex) 
fused with maltose binding protein (MBP) was crystallized to investigate the 
molecular mechanism of Charcot-Marie-Tooth disease subtype 1B. Based on 
the wild type structure of the extracellular domain of the human myelin protein 
zero, five clinically important mutants were further structurally investigated in 
details. The molecular pathology was proposed for these mutants individually. 
The relationship between amyloidosis disease and CMT1B is being further 
explored. From a technical point of view,the WT hP0ex MBP fusion structure 
was another example of crystallographic studies facilited by the presence of a 
purification and crystallization protein tag, the maltose binding protein. 
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